A vaccine for treatment or prevention of verotoxin-producing escherichia coli (VTEC) infection

A vaccine using specific subunit antigens involved in VTEC attachment offers protection against VTEC infections and HUS, addressing the limitations of current vaccines and treatments by inducing broad immunity in humans and bovines.

WO2024018083A9PCT designated stage expired Publication Date: 2024-11-28UNIV COLLEGE DUBLIN NAT UNIV OF IRELAND DUBLIN
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2023/070365
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-07-21
Filing Date
2023-07-21
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current vaccines for verotoxin-producing Escherichia coli (VTEC) infections are limited, and there is a need for a vaccine that can prevent colonization and subsequent Haemolytic Uraemic Syndrome (HUS) in children, as existing treatments are ineffective and antibiotics can exacerbate the condition.

Method used

Development of a vaccine using multiple subunit antigens such as putative phage inhibition, colicin resistance, and tellurite resistance protein (TerD), glutamine-binding periplasmic protein (GlnH), multidrug resistance protein (MdtE), and putative periplasmic binding transport protein, which are involved in VTEC attachment to host cells, to induce protective immunity against a range of VTEC strains.

Benefits of technology

The vaccine provides protective immunity against VTEC infection, reducing colonization and the risk of HUS, and can be used in both humans and bovines, addressing the economic and health burdens of VTEC outbreaks.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure EP2023070365_28112024_PF_FP_ABST
    Figure EP2023070365_28112024_PF_FP_ABST
Patent Text Reader

Abstract

A vaccine comprising one or more VTEC immunogens. The vaccine is for use in vaccine therapy to treat or prevent VTEC infection in a mammal and for use in vaccine therapy to treat or prevent HUS in a mammal. A method of diagnosing VTEC infection in a subject is also provided.
Need to check novelty before this filing date? Find Prior Art

Description

[0001]Title of the Invention A vaccine for treatment or prevention of verotoxin-producing Escherichia coli (VTEC) infection. Field of the Invention The current invention relates to a vaccine for treatment or prevention of verotoxin-producing Escherichia coli (VTEC) infection in mammals, particularly in humans. The invention also relates to a method for diagnosing VTEC infection in a mammal. Background to the Invention Verotoxin-producing E. coli (VTEC) (also known as Enterohemorrhagic E. coli or Shiga toxin producing E. coli are predominantly foodborne pathogens which cause severe bloody diarrhoea. They are initially ingested by ruminants, predominantly cattle, which act as symptomatic carries of the disease. This allows easy access into the environment leading to transmission in humans. Children and adults are usually infected by either consuming contaminated food and water or contact with livestock faeces in the environment. Consumption of improperly cooked meat, raw fresh produce, or water from faecal contaminated sources, are frequent sources of human VTEC infection. Recent data have shown that raw flour and undercooked baked products containing flour, have caused outbreaks (Verrill, A.M., et al., Journal of Food Protection, Volume 85, Issue 1, 2022, pages 31-35). The economic costs can be substantial. In the United States, the costs of healthcare, social care, and lost productivity are estimated to be $600 million per year, whereas costs to the food industry from product recalls and reduced trade can run to tens of millions of dollars. Ireland currently has the highest level of VTEC incidence in Europe with an incidence rate of 16.3 cases per 100,000 population (www.ecdc.europa.eu), compared to 2.22 cases per 100,000 in EU / EEA as reported by ECDC report 2019. VTEC O157:H7 is the predominant serotype associated with large and severe outbreaks (Pierard, D., et al (2012) Vet Res, 43(1), pp.13). However, epidemiological studies indicate that non-O157 VTEC strains make up half of the VTEC cases in Europe (ECDC report). The incidence and severity of infection is greatest in children under five. Severe VTEC infections can lead to Haemolytic Uraemic Syndrome (HUS), which is the main cause of kidney failure among young children. In Ireland between 2009-2012, 12% of children with VTEC developed HUS (HSPC report). HUS can cause other life-long complications including blindness, bowel perforation and seizures. Currently, there are no vaccines available to protect children from VTEC infections. Vaccine development has been limited to a small number of virulence factors (Garcia-Angulo, V.A., (2014) Comparative genomics and immunoinformatics approach for the identification of vaccine candidates for enterohemorrhagic Escherichia coli O157: H7. Infection and immunity, 82(5), 2016-2026). This study identified a list of 65 candidates. A pool containing three (Lom-like protein (pVAX-31), a putative pilin subunit (PVAX-12) and a fragment of the type III secretion structural protein EscC (pVAX-56-2)) was shown to be capable of inducing an immune response. One candidate EscC was considered to have potential to reduce colonisation when used individually. Antibiotics are occasionally used for the treatment of VTEC infection in patients, despite being contraindicated. In general, it is recommended that patients with VTEC infection should not be treated with antibiotics owing to an enhanced risk of HUS and kidney complications in patients. Antibiotics increase the potential for VTEC to release toxin. When it occurs, HUS is usually treated in an intensive care unit, with the requirement of blood transfusions and kidney dialysis. Because cattle are asymptomatic carriers, they are not generally treated for VTEC colonisation. Moreover, there is no incentive for farmers to vaccinate, as the farmer would need to bear the cost of vaccination even though prevention of colonisation in cattle bring no economic benefit to them. Adhesins are promising candidates for the development of a prophylactic vaccine against VTEC infections (Wizemann, T. M. et al, (1999) Emerging infectious diseases, 5(3), pp.395- 403). As VTEC harbours multiple proteins with varying degrees of interaction with the intestinal epithelia, it is highly probable that novel protein adhesins have yet to be discovered (McWilliams, B. D. and Torres, A. G., (2014). Microbiol Spectr, 2(3); Tobe, T. et al, (2006) Proceedings of the National Academy of Sciences – PNAS, 103(40), pp.14941-14946), which may be common among O157 and non-O157 strains and not found in commensal E. coli. There is an unmet need to provide a vaccine to prevent VTEC infections in childhood would reduce mortality and reduce the greatest risk of kidney failure in children. It is an objective of the invention to overcome at least one of the above-referenced problems. Summary of the Invention The inventors have identified VTEC proteins for use in a vaccine that can prevent colonisation of subjects with VTEC and in turn prevent HUS. Thus, the invention provides proteins, which provide protective immunity against infection. The use of multiple subunit antigens widens the protective response against bacterial infection amongst a greater range of strains of the bacterium. The vaccine antigens are as follows (herein “proteins of the invention”): ^ Putative phage inhibition, colicin resistance and tellurite resistance protein (TerD) ^ Uncharacterized protein YiaF ^ Glutamine-binding periplasmic protein (GlnH) ^ Phosphoenolpyruvate-protein phosphotransferase (PPP) ^ Multidrug resistance protein (MdtE) ^ Putative periplasmic binding transport protein The inventors are the first to discover that these proteins are involved in the attachment of VTEC to the host cells, in particular to human gastrointestinal cells. For example, Figure 1 illustrates that GlnH protein is involved in host cell attachment. In addition, the inventors confirmed that GlnH protein was a highly immunogenic B-cell antigen in a mouse model (Figure 3). Figure 4 confirms that immunised mice showed protection from E. coli O157:H7. The proteins are expressed in VTEC strains, such as VTEC O157:H7 strains, and are not identified in attachment of commensal strains. The inventors have also discovered that the proteins of the invention (or genes encoding said proteins) may be used in a diagnostic method for VTEC infection in a mammal. In an aspect, the invention provides at least one VTEC immunogen, (or a nucleotide, or mRNA, encoding the immunogen) for use in vaccine therapy to treat or prevent VTEC infection in a mammal, wherein the at least one VTEC immunogen is selected from the group comprising a TerD, YiaF, GlnH, PPP, MdtE and putative periplasmic binding transport protein immunogen (herein referred to as “immunogen of the invention”). In an aspect, the invention provides at least one VTEC immunogen of the invention, (or a nucleotide, or mRNA, encoding the immunogen) for use in vaccine therapy to treat or prevent HUS in a mammal, wherein the at least one VTEC immunogen is selected from the group comprising a TerD, YiaF, GlnH, PPP, MdtE and putative periplasmic binding transport protein immunogen. An aspect of the invention provides a vaccine comprising at least one immunogen of the invention (or a nucleotide or mRNA encoding the immunogen) (herein “vaccine of the invention”). The vaccine of the invention is for treating or preventing VTEC infection in a mammal. The vaccine may be for treating or preventing HUS in a mammal. In an embodiment of the above aspects, the at least one VTEC immunogen of the invention is a protein, or an immunogenic portion of the protein. Thus, in an embodiment, the immunogenic portion may be a polypeptide or a peptide. In a further embodiment, the vaccine may comprise a fusion of one or more immunogens or a mixture of immunogens. The polypeptide may be one or more of SEQUENCE ID NO.1 to 6 or a therapeutically effective variant thereof. In an embodiment, the vaccine of the invention may comprise (or consist of) all of the immunogens of the invention. In an embodiment, the vaccine of the invention may comprise an immunogenic portion, or combination of immunogenic portions, from each protein of the invention. In an embodiment, the vaccine may comprise a nucleotide sequence or mRNA encoding said immunogen, e.g., protein, or a VTEC polypeptide. The nucleotide sequence may be one or more of SEQUENCE ID NO. 7 to 12, or a therapeutically effective variant thereof. Optionally, the vaccine of the invention comprises one or more adjuvants. The vaccine of the invention may include one or more additional antigens. Preferably, the VTEC infection is caused by a VTEC strain selected from but not limited to VTEC O157:H7, VTEC O26, VTEC O111, VTEC O103, VTEC O121, VTEC O45 and VTEC O145. Typically, the VTEC strain is VTEC O157:H7. In an embodiment, the mammal is a human. The human may be any age. In an embodiment, the human may be a human 15 years old or younger, or 12 years old or younger, typically 7 years old or younger. In an embodiment, the human may be 60 years old or older. In an embodiment, the human may be from 15 to 60 years of age. In an embodiment, the mammal is a bovine. It can be a cow, heifer, calf, or a bull. The invention also relates to a pharmaceutical composition comprising one or more immunogens of the invention and a pharmaceutically acceptable excipient. The composition may also include one or more additional antigens. An aspect of the invention provides a method for diagnosing VTEC infection in a mammal, said method comprising assaying a sample from said mammal for the presence of one or more proteins of the invention (or a gene encoding the protein of the invention), wherein presence of said one or more proteins in the sample is indicative of VTEC infection in the mammal. In this aspect, the proteins of the invention also include FkpA protein. Preferably, the one or more proteins are selected from FkpA, GlnH, YiaF and TerD. In an embodiment, the proteins selected are FkpA, GlnH, YiaF. Definitions and general preferences Where used herein and unless specifically indicated otherwise, the following terms are intended to have the following meanings in addition to any broader (or narrower) meanings the terms might enjoy in the art: Unless otherwise required by context, the use herein of the singular is to be read to include the plural and vice versa. The term "a" or "an" used in relation to an entity is to be read to refer to one or more of that entity. As such, the terms "a" (or "an"), "one or more," and "at least one" are used interchangeably herein. As used herein, the term "comprise," or variations thereof such as "comprises" or "comprising," are to be read to indicate the inclusion of any recited integer (e.g. a feature, element, characteristic, property, method / process step or limitation) or group of integers (e.g. features, element, characteristics, properties, method / process steps or limitations) but not the exclusion of any other integer or group of integers. Thus, as used herein the term "comprising" is inclusive or open-ended and does not exclude additional, unrecited integers or method / process steps. As used herein, the term “disease” is used to define any abnormal condition that impairs physiological function and is associated with specific symptoms. The term is used broadly to encompass any disorder, illness, abnormality, pathology, sickness, condition, or syndrome in which physiological function is impaired irrespective of the nature of the aetiology (or indeed whether the aetiological basis for the disease is established). It therefore encompasses conditions arising from infection, trauma, injury, surgery, radiological ablation, poisoning, or nutritional deficiencies. As used herein, the term "treatment" or "treating" refer to an intervention (e.g. the administration of an agent to a subject) which cures, ameliorates or lessens the symptoms of a disease or removes (or lessens the impact of) its cause(s). In this case, the term is used synonymously with the term “therapy”. It can be manifested by a permanent or temporary improvement in the subject's condition. In this context it includes limiting and / or reversing disease progression. As used herein the terms "prevention" or "preventing" refer to an intervention (e.g., the administration of an agent or vaccine to a subject), which prevents or delays the onset or progression of a disease or infection, e.g., VTEC infection, or the severity of a disease in a subject, or reduces (or eradicates) its incidence within a treated population. When used herein, the term “composition” should be understood to mean something made by the hand of man, and not including naturally occurring compositions. Compositions may be formulated in unit dosage form, i.e., in the form of discrete portions containing a unit dose, or a multiple or sub-unit of a unit dose. When used herein, the term “pharmaceutical composition” may comprise one or more pharmaceutically acceptable diluents, excipients or carriers. Even though the peptides and compositions of the present invention can be administered alone, they will generally be administered in admixture with a pharmaceutical carrier, excipient or diluent, particularly for human therapy. The pharmaceutical compositions may be for human or animal usage in human and veterinary medicine. Examples of such suitable excipients for the various different forms of pharmaceutical compositions described herein may be found in the “Handbook of Pharmaceutical Excipients”, 2ndEdition, (1994), edited by A Wade and PJ Weller. In particular, formulations for topical delivery are described in “Topical Drug Delivery Formulations” edited by David Osborne and Antonio Aman, Taylor & Francis, the complete contents of which are incorporated herein by reference. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit.1985). The term “sequence homology” should be understood to mean sequence identity and similarity, i.e. a polypeptide sequence that shares 90% sequence identity with a sequence is one in which any 90% of aligned residues are either identical to, or conservative substitutions of, the corresponding residues said sequence. Preferably the term means sequence identity and it is over the entire length of the sequence. Sequence homology can be calculated by a BLAST program (www.ncbi.nlm.nih.gov / cgi-bin Blast). The term “peptide” used herein refers to a polymer, generally composed of up to 50 amino acids, for example 5 to 50 amino acid monomers typically linked via peptide bond linkage. Peptides (including fragments and variants thereof) of and for use in the invention may be generated wholly or partly by chemical synthesis or by expression from nucleic acid. For example, the peptides of and for use in the present invention can be readily prepared according to well-established, standard liquid or, preferably, solid-phase peptide synthesis methods known in the art (see, for example, J. M. Stewart and J. D. Young, Solid Phase Peptide Synthesis, 2nd edition, Pierce Chemical Company, Rockford, Illinois (1984); and M. Bodanzsky and A. Bodanzsky, The Practice of Peptide Synthesis, Springer Verlag, New York (1984)). When necessary, any of the peptides employed in the invention can be chemically modified to increase their stability. A chemically modified peptide or a peptide analog includes any functional chemical equivalent of the peptide characterized by its increased stability and / or efficacy in vivo or in vitro in respect of the practice of the invention. The term subject (which is to be read to include "individual", "animal", "patient" or "mammal" where context permits) defines any subject, particularly a mammalian subject, for whom treatment or prevention is indicated. Mammalian subjects include, but are not limited to, humans, domestic animals, farm animals, zoo animals, sport animals, pet animals, such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, camels, bison, cattle, cows; primates such as apes, monkeys, orangutans, and chimpanzees; canids such as dogs and wolves; felids such as cats, lions, and tigers; equids such as horses, donkeys, and zebras; food animals such as cows, pigs, and sheep; ungulates such as deer and giraffes; and rodents such as mice, rats, hamsters and guinea pigs. In preferred embodiments, the subject is a human or a cow. As used herein, the term “equine” refers to mammals of the family Equidae, which includes horses, donkeys, asses, kiang and zebra. The term “VTEC infection” is understood to mean infections or colonisation of mammals that are caused by a strain of Verotoxin-producing E. coli. An example includes VTEC O157:H7 strains. It may be an asymptomatic infection or colonisation of VTEC. The term “immunogen” is a substance that is capable of generating a B-cell and / or T-cell immune response in a host organism. In this context, the immunogen may be a protein or an immunogenic portion of the protein such as an isolated polypeptide, or peptide. The term “immunogenic portion” as applied to a protein of the invention should be understood to mean a portion of the protein of the invention, e.g., a peptide or polypeptide, that when administered to a mammal elicits an immune response specific to the portion that is administered. The immunogenic portion is either a B-cell or T-cell epitope. The term “vaccine therapy” should be understood to mean the administration of an immunogen, e.g., a protein or immunogenic portion thereof or an mRNA or viral vector encoding the protein, to a mammal with a view to eliciting a response by the host immune system. Typically, it results in the immunogen being destroyed and subsequently recognised by the host immune system. The term “immune response” should be understood to mean induced humoral or cellular response in a host subject. As used herein, the term “active pharmaceutical ingredient” or “API” refers to an immunogen that may be used in vaccine therapy such as a protein, protein subunit, polypeptide, botanical (e.g., a plant extract) a fraction of a cell such as a bacterial cell, viral cell, or yeast cell (e.g. a cell wall fraction), or a nucleic acid encoding an immunogen. The nucleic acid may be a RNA (e.g. mRNA) or DNA molecule. In this specification, the term “vaccine” should be understood to mean a composition comprising at least one immunogen, e.g., a protein of the invention, and optionally a suitable adjuvant and / or carrier. The preparation of vaccines comprising a protein or peptide as an active agent is well known in the art, for example US4599230 and US4601903 as examples. The term “DNA vaccine” should be understood to mean a composition that comprises a nucleic acid, typically on nucleic acid construct that is capable of being delivered to a subject and encodes one or more proteins or immunogenic portions of the invention. The nucleic acid construct expresses said one or more protein or immunogenic portions in said subject. The protein or immunogenic portion thereof may be expressed as separate entities or in the form of a fusion protein. The vaccine may include one or more suitable adjuvants and / or one or more suitable pharmaceutically acceptable carriers. The construct may be an expression vector. Expression vectors suitable for this purpose are known in the art, for example a plasmid or a virus. In an embodiment, the vector is an adenovirus vector. The term “adjuvant” should be understood to mean an agent that enhances the subject, i.e., the recipient’s, immune response to an immunogenic protein or portion thereof. Details of a suitable adjuvant composition are well known to a person skilled in the art. The term “immunogenic composition” refers to a composition comprising one or more proteins of the invention, or an immunogenic portion thereof, that is capable of inducing an immune response in an individual. Proteins, peptides, and polypeptides (and their variants, including fragments) of and for use in the invention may be generated wholly or partly by chemical synthesis or by expression from nucleic acid. The proteins and peptides of and for use in the present invention can be readily prepared according to well-established, standard liquid or, preferably, solid-phase peptide synthesis methods known in the art (see, for example, J. M. Stewart and J. D. Young, Solid Phase Peptide Synthesis, 2nd edition, Pierce Chemical Company, Rockford, Illinois (1984), in M. Bodanzsky and A. Bodanzsky, The Practice of Peptide Synthesis, Springer Verlag, New York (1984). In this specification the term “amount effective” or “therapeutically effective amount” should be taken to mean an amount which results in a clinically significant reduction or prevention of VTEC infection. Suitably, the immunogenic component of the vaccine is administered at a dose of from 1µg to 100µg. In one embodiment, it is administered at a dose of from 10µg to 70µg, or from 10µg to 50µg, or from 20µg to 40µg, or from 25µg to 30µg. Typically, it is given as a bolus dose. In the context of the therapeutic aspects of the present invention, the term “individual in need thereof” shall be taken to mean a mammal, preferably a human, who has an infection caused by a VTEC strain. In therapeutic aspects which include prevention, the term “individual in need thereof” can also include a bovine animal who is at risk of developing an infection caused by a VTEC strain. The term "symptom" is defined as an indication of disease, illness, injury, or that something is not right in the body. In this specification, the term “at least one” should be understood to mean and encompass that at least one, at least two, at least three, at least four, at least five, at least six, at least seven, or all immunogens and for example in the context of the vaccine or composition of the invention can be selected from the group consisting of TerD, YiaF, GlnH, PPP, MdtE and putative periplasmic binding transport protein, immunogens. The term "excipient" refers to a diluent, adjuvant, carrier or vehicle with which the therapeutic or active is administered. Such pharmaceutical carriers or excipients can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol and the like. The vaccine or composition of the invention can be formulated in any suitable means for the desired route of administration. Formulation should suit the mode of administration. Various delivery systems are known and can be used to administer a therapeutic of the invention, e.g., intra-nasally or orally. It may be in the form of a particle. It may be formulated as a nanoparticle or microparticle, preferably biodegradable. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, intranasal, intracerebral, and oral routes. The vaccine or compositions may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with adjuvants and or other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent. In this specification, Glutamine binding periplasmic protein (GlnH) is a protein that is expressed by pathogenic VTEC strains, for example, VTEC O157:H7 strains. The protein has an approximate molecular weight of 27kDa and an approximate PI of 8.44. The term GlnH encompasses this protein and therapeutically effective variants that share at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with SEQUENCE ID NO.1. The amino acid sequence of GlnH expressed by VTEC is provided in SEQUENCE ID NO.1. The nucleic acid sequence of GlnH s provided in SEQUENCE ID NO.6. In this specification, TerD is tellurite resistance protein and is a stress response protein that is associated with membrane linked metal recognition complexes. TerD has a molecular weight of 20.4 with a pI of 4.64. (Peng, W.; et al., Microorganisms 2022, 10, 95). The term TerD encompasses this protein and therapeutically effective variants that share at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with SEQUENCE ID NO: 2. In this specification, Yia-F is an uncharacterised lipoprotein that has been shown to stimulate toll like receptor 2. Yia-F has a molecular weight of 25.7 with a pI of 6.08. (Burgess et al., J Immunol October 15, 2018, 201 (8) 2377-2384). The term Yia-F encompasses this protein and therapeutically effective variants that share at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with SEQUENCE ID NO: 3. (PtsI / PPP) phosphoenolpyruvate-protein phosphotransferase has a pI of 4.78 and a molecular weight of 63.7 kDa. The term PPP encompasses this protein and therapeutically effective variants that share at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with SEQUENCE ID NO: 4. MtdE is anaerobic multidrug efflux transporter expressed by VTEC strains. The term MtdE encompasses this protein and therapeutically effective variants that share at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with SEQUENCE ID NO: 5. The term putative periplasmic binding transport protein encompasses this protein expressed by VTEC strains and therapeutically effective variants that share at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with SEQUENCE ID NO: 6. In this specification, the term “therapeutically effective variant” as applied to a VTEC protein means a protein that shares at least 90% sequence homology with the protein amino acid sequence and that is capable of eliciting a protective immune response in a mammal immunised with the variant against subsequent challenge by VTEC. An “mRNA vaccine” is a vaccine that uses a copy of messenger RNA (mRNA) to produce an immune response. The vaccine delivers the immunogen encoding mRNA into the subject’s immune cells. This uses the mRNA to provide the protein, in this case the VTEC protein. It is translated in the cell cytosol. This protein then stimulates the immune response which teaches the body to identify and destroy the pathogen. Typically, the mRNA is delivered by a co- formulation of the RNA encapsulated in a lipid nanoparticle that protects the RNA strand and aids absorption into the cells. Methods to make mRNA and mRNA vaccines are known in the art. mRNA vaccines are described in Kowalski PS, Rudra A, Miao L, Anderson DG (April 2019). "Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery". Mol Ther.27 (4): 710–28; and Verbeke R, Lentacker I, De Smedt SC, Dewitte H (October 2019). "Three decades of messenger RNA vaccine development". Nano Today.28: 100766. In this specification, the term “biological sample” or “biological fluid” may be a sample obtained from an individual such as, for example, urine or urine cell-sediment, blood, saliva, or a tissue sample. In many cases, the subject will be a mammal suspected of having VTEC infection, or at risk of having a VTEC infection. Brief Description of the Figures Figure 1. Attachment of VTEC strain O157 to HT29 and Caco-2 cells. Representative 2-D blots of OMPs from VTEC O157 strain NCTC 12900 probed with 1x106cell / ml HT29 cells (A) or 1x106cell / ml CaCo-2 cells (B). Cells were detected with anti-epithelial antibody. 2D gel and blot are representative of at least three independent experiments in each case. Figure 2. Induced BL21 cells expressing GlnH protein increased the level of bacterial attachment to gastrointestinal cells compared to uninduced BL21 cells in vitro. The level of attachment of induced and uninduced BL21 cells recombinantly expressing protein GlnH to gastrointestinal cells (HT29 and CaCo-2). Each error bar represents mean + SEM from four independent experiments. Significant differences in adhesion were analysed by one-way ANOVA Sidak’s multiple comparison test (*, p < 0.05). Figure 3. A) Timeline of three dose immunisation schedule. The figure shows a schematic of GlnH immunisation of BALB / c mice and bacterial challenge with E. coli O157:H7 prototype strain NCTC12900Nalr, followed by blood, faeces, and organ collection. B) Serological analysis of specific total IgG, responses to three dose GlnH immunisation in mice. Levels of Total IgG, produced in response to 3 dose GlnH immunisation. Sera were obtained by blood collection 7 days after third immunisation dose. All antibody titres were determined by OD at 450nm at each titration event. Difference in total IgG titres raised against GlnH in immunised and non-immunised groups were statistically compared by one-way ANOVA Sidak’s multiple comparison test (****, p < 0.0001); (**, p < 0.01) Figure 4. The effect of vaccination and O157 challenge on faecal shedding and weight gain in BLBC / c mice. Faecal shedding was monitored daily to access protection conferred against E. coli O157 NCTC Nalr6 days post challenge. The daily level of E. coli O157 shed from mice faeces are represented by scatter plots as mean CFU + std deviation (SD) of two independent faecal collections from each group. Significant differences in daily NCTC12900Nalrshed between groups were determined via two-way ANOVA Tukey’s multiple comparison test (*, p < 0.05)(Fig 5A). The weight of mice in each treatment group were recorded daily for 7 days to determine percentage weight gain post bacterial challenge. The data is represented using scatter plots as mean percent initial weight (%) + standard deviation (SD) of all appropriate mice from each treatment group per gender. Significant differences in daily weight gain (%) between groups were determined via two-way ANOVA Tukey’s multiple comparison test. The levels of significance are represented as follows: (*, p < 0.05); (**, p < 0.01); (***, p < 0.001)(Fig 5B). Figure 5. Timeline of two dose immunisation schedule. The figure shows a schematic of GlnH immunisation of BALB / c mice using either a B-cell or T-cell inducing adjuvant and bacterial challenge with E. coli O157:H7 prototype strain NCTC12900Nalr, followed by blood, faeces, and organ collection. Figure 6. Serological analysis of immune response to two dose GlnH immunisation in mice. GlnH-specific IgG, IgG2a and IgG1 titres were examined in immunised (10ug GlnH with either SAS or alum) and non-immunised (SAS or alum only) groups by indirect ELISA. Sera were obtained by blood collection 28 days after second immunisation dose. All antibody titres were determined by OD at 450nm at each titration event. Difference in total IgG, IgG2a and IgG1 titres raised against GlnH in individual treatment groups were statistically compared by one-way ANOVA Sidak’s’s multiple comparison test (****, p < 0.0001). Figure 7. GlnH immunisation dosing showed better levels of protection against O157 infection. Seven days post bacterial challenge via oral gavage with 4 x 109CFU with E. coli prototype strain NCTC 12900 Nalr, the large intestine plus caecum were collected from each mouse after Euthanasia by CO2exposure. Bacterial burden was determined per gram of tissue and level of colonisation were expressed in log scale. All colonisation data are displayed as means + standard errors of the mean (SEM) of results obtained per treatment group. Significant difference of NCTC12900Nalrcolonisation in the GI tract of mice were analysed using an unpaired t-test (*, p < 0.05). Figure 8 (A to F): Identification of proteins involved in VTEC and Commensal E. coli attachment to gastrointestinal cells using a cell blot. Representative PageBlue stained 2D gels (A and D) and cell-probed blots (B, C, E and F) for pathogenic E. coli strain O157:H7 (A to C) and the commensal E. coli strain, HS (D to F). Blots in panels B and E were probed with 1x106cells / mL HT29 cells, while blots in panels C and F were probed with 1x106cells / mL CaCo-2 cells. Figure 9: Screen for positive, Top10 uptake of FkpA vector insert and transformants containing the FkpA vector insert. Lane 1: DNA ladder 1Kbp ladder, lane 2: positive uptake of FkpA vector in Top10 competent cells, lanes 3-4: positive FkpA transformants into BL21 expression host. Lane 5: water control. Figure 10: Schematic diagram workflow used to determine the antigen prevalence of FkpA, GlnH, YiaF and TerD genes using RT-PCR Figure 11: Appearance of VTEC colonies on CHROMagarTM STEC. E. coli VTEC have mauve colour. Detailed Description of the Invention All publications, patents, patent applications and other references mentioned herein are hereby incorporated by reference in their entireties for all purposes as if each individual publication, patent or patent application were specifically and individually indicated to be incorporated by reference and the content thereof recited in full. A vaccine, particularly for human use, would protect the population from VTEC infection. The current inventors identified a set of VTEC proteins involved in the attachment of VTEC to host cells. Immunisation with these antigens prevents colonisation of vulnerable subjects, such as children, with VTEC. This in turn prevents HUS. The vaccine of the invention also has a use in bovine. Bovine, such as cows, are asymptomatic carriers of VTEC and are a common source of VTEC infection. Prophylactic vaccination of bovine on the farm would prevent the colonised / contaminated meat from entering the supply chain and prevent one avenue of invention in humans. The immunogens of the invention are the proteins of the invention or immunogenic portions thereof, such as a polypeptide. The proteins of the invention are listed in Table 1. Protein Name NCBI Sequence ID Putative phage inhibition, colicin resistance WP_000116680.1. and tellurite resistance protein (TerD) Uncharacterized protein YiaF WP_000190516.1. NP_312466.2 Glutamine-binding periplasmic protein WP_000843866.1. NP_308916.1 (GlnH) Multidrug resistance protein (MdtE) WP_001082000.1 NP_312420.1 Putative periplasmic binding transport WP_001302033.1 NP_310686.1 protein Phosphoenolpyruvate-protein WP_000623136.1 NP_311315.1 phosphotransferase Table 1: Proteins of the invention and NCBI sequence. The amino acid and nucleotide sequences of the immunogens of the invention are as follows: Amino Acid Sequences (GlnH) Glutamine-binding periplasmic protein SEQUENCE ID NO.1. MKSVLKVSLAALTLAFAVSSHAADKKLVVATDTAFVPFEFKQGDKYVGFDVDLWAAIAKE LKLDYELKPMDFSGIIPALQTKNVDLALAGITITDERKKAIDFSDGYYKSGLLVMVKANN NDVKSVKDLDGKVVAVKSGTGSVDYAKANIKTKDLRQFPNIDNAYMELGTNRADAVLHDT PNILYFIKTAGNGQFKAVGDSLEAQQYGIAFPKGSDELRDKVNGALKTLRENGTYNEIYK KWFGTEPK (Ter D) Tellurium resistance protein SEQUENCE ID NO.2. MSVSLSKGGNVSLSKAAPSMKNVLVGLGWDARSTDGQDFDLDASAFLLASNGKVRGDSDFIF YNNLTSSDGSVTHTGDNRTGEGDGDDESLKIKLDAVPSEVDKIIFVVTIHDAQARRQSFGQV SGAFIRLVNDDNQTEVARYDLTEDASTETAMLFGELYRHNGEWKFRAVGQGYAGGLASVCAQ YGINAS (YiaF) Barrier effect co-colonisation resistance factor SEQUENCE ID NO.3. MATGKSCSRWFAPLAALLMVVSLSGCFDKEGDQRKAFIDFLQNTVMRSGERLPTLTADQK KQFGPFVSDYAILYGYSQQVNQAMDSGLRPVVDSVNAIRVPQDYVTQSGPLREMNGSLGV LAQQLQNAKLQADAAHSALKQSDDLKPVFDQAFTKVVTTPADALQPLIPAAQTFTQQLVM VGDYIAQQGTQVSFVANGIQFPTSQQASEYNKLIAPLPAQHQAFNQAWTTAVTATQ (PtsI / PPP) phosphoenolpyruvate-protein phosphotransferase a.k.a. phosphotransferase system enzyme I PtsI SEQUENCE ID NO.4. MISGILASPGIAFGKALLLKEDEIVIDRKKISADQVDQEVERFLSGRAKASAQLETIKTK AGETFGEEKEAIFEGHIMLLEDEELEQEIIALIKDKHMTADAAAHEVIEGQASALEELDD EYLKERAADVRDIGKRLLRNILGLKIIDLSAIQDEVILVAADLTPSETAQLNLKKVLGFI TDAGGRTSHTSIMARSLELPAIVGTGSVTSQVKNDDYLILDAVNNQVYVNPTNEVIDKMR AVQEQVASEKAELAKLKDLPAITLDGHQVEVCANIGTVRDVEGAERNGAEGVGLYRTEFL FMDRDALPTEEEQFAAYKAVAEACGSQAVIVRTMDIGGDKELPYMNFPKEENPFLGWRAI RIAMDRKEILRDQLRAILRASAFGKLRIMFPMIISVEEVRALRKEIEIYKQELRDEGKAF DESIEIGVMVETPAAATIARHLAKEVDFFSIGTNDLTQYTLAVDRGNDMISHLYQPMSPS VLNLIKQVIDASHAEGKWTGMCGELAGDERATLLLLGMGLDEFSMSAISIPRIKKIIRNT NFEDAKVLAEQALAQPTTDELMTLVNKFIEEKTIC MtdE anaerobic multidrug efflux transporter SEQUENCE ID NO.5. MNRRRKLLIPLLFCGAMLTACDDKSAENTAAMTPEVGVVTLSPGSVNVLSELPGRTVPYE VAEIRPQVGGIIIKRNFIEGDKVNQGDSLYQIDPAPLQAELNSAKGSLAKALSTASNARI TFNRQASLLKTNYVSRQDYDTARTQLNEAEANVTVAKAAVEQATINLQYANVTSPITGVS GKSSVTVGALVTANQADSLVTVQRLDPIYVDLTQSVQDFLRMKEEVASGQIKQVQGSTPV QLNLENGKRYSQTGTLKFSDPTVDETTGSVTLRAIFPNPNGDLLPGMYVTALVDEGSRQN VLLVPQEGVTHNAQGKATALILDKDDVVKLREIEASKAIGDQWVVTSGLQAGDRVIVSGL QRIRPGIKARAISSSQENASTESKQ Putative periplasmic binding transport protein SEQUENCE ID NO.6. MKLAHLGRQALMGVMAVALIAGMSVKSFADEGLLNKVKERGTLLVGLEGTYPPFSFQGDD GKLTGFEVEFAQQLAKHLGVEASLKPTKWDGMLASLDSKRIDVVINQVTISDERKKKYDF STPYTISGIQALVKKGNEGTIKTADDLKGKKVGVGLGTNYEEWLRQNVQGVDVRTYDDDP TKYQDLRVGRIDAILVDRLAALDLVKKTNDTLAVTGEAFSRQESGVALRKGNEDLLKAVN DAIAEMQKDGTLQALSEKWFGADVTK Nucleotide Sequences (GlnH) Glutamine-binding periplasmic protein SEQUENCE ID NO.7. 1 atgaagtctg tattaaaagt ttcactggct gcactgaccc tggcttttgc ggtttcttct 61 catgccgcgg ataaaaaatt agttgtcgcg acggataccg ccttcgttcc gtttgaattt 121 aaacagggcg ataaatatgt gggctttgac gttgatctgt gggctgccat cgctaaagag 181 ctgaagctgg attacgaact gaagccgatg gatttcagtg ggatcattcc ggcactgcaa 241 accaaaaacg tcgatctggc gctggcgggc attaccatca ccgacgagcg taaaaaagcg 301 atcgatttct ctgacggcta ctacaaaagc ggcctgttag tgatggtgaa agctaacaat 361 aacgatgtga aaagcgtgaa agatctcgac gggaaagtgg ttgctgtgaa gagcggtact 421 ggctccgttg attacgcgaa agcaaacatc aaaactaaag atctgcgtca gttcccgaac 481 atcgataacg cctatatgga actgggcacc aaccgcgcag acgccgttct gcacgatacg 541 ccaaacattc tgtacttcat caaaaccgcc ggtaacggtc agttcaaagc ggtaggtgac 601 tctctggaag cgcagcaata cggtattgcg ttcccgaaag gtagcgacga gctgcgtgac 661 aaagtcaacg gcgcgttgaa aaccctgcgc gagaacggaa cttacaacga aatctacaaa 721 aaatggttcg gtactgaacc gaaataa (Ter D) Tellurium resistance protein SEQUENCE ID NO.8. 1 atgagtgttt ctctttccaa aggcgggaac gtctccctga gtaaagcagc tccgtcaatg 61 aaaaatgtcc tggtgggcct tggctgggat gcgcgttcaa cagacggtca ggactttgac 121 ctggatgctt cagcattcct gctggcctca aacggcaaag tgcgcggcga ttcagatttc 181 atcttctata acaacctgac gtcatccgac ggttccgtaa cgcacaccgg cgataaccgc 241 accggtgagg gcgatggtga tgatgaatcg ctgaaaatta aactggacgc cgtcccgtct 301 gaagttgaca agatcatctt cgttgtgacc atccacgatg ctcaggctcg tcgccagagc 361 tttggtcagg tatccggtgc gtttattcgt ctggttaatg acgataacca gactgaagtc 421 gctcgctacg atctgaccga agatgcgtcc actgagactg ccatgctgtt cggcgagctg 481 tatcgccaca atggtgagtg gaaattccgc gcagtaggcc agggttatgc tggtggtctg 541 gcatctgtat gtgctcagta cggcattaac gcgtcctga (YiaF) Barrier effect co-colonisation resistance factor SEQUENCE ID NO.9 1 atggcgacag gaaagtcctg ctctcgctgg tttgcgcctc ttgcggcgtt attaatggta 61 gttagcctga gtgggtgttt tgataaagaa ggcgatcagc gtaaagcgtt tatcgacttc 121 ctgcagaata cagtgatgcg tagcggtgaa cgtctaccaa ccctgactgc cgatcagaaa 181 aaacagtttg gtccttttgt ctctgattac gcgattctgt atggttattc tcagcaggtg 241 aatcaggcga tggattccgg tctgcgcccg gttgtagaca gcgttaacgc aattcgcgta 301 ccgcaggatt acgttacgca aagcggtccg ctgcgtgaaa tgaatggttc gctgggtgtg 361 ctggcgcaac aactgcaaaa tgcgaagttg caggccgatg ctgcgcactc tgcgctaaaa 421 cagagtgatg acctgaaacc ggtctttgat caggcattca ccaaagtggt aacgacgcca 481 gctgatgcat tgcaaccgtt gattccggcg gcacaaactt tcacgcaaca actggtgatg 541 gttggagact acattgccca acaaggtact caggtgagct ttgtagcaaa tggcatccag 601 ttcccgactt cacagcaggc aagtgaatat aacaaactga ttgcgccatt accggcacaa 661 catcaggcgt ttaatcaggc ctggactaca gcagttactg caacccaata a (PtsI / PPP) phosphoenolpyruvate-protein phosphotransferase a.k.a. phosphotransferase system enzyme I PtsI SEQUENCE ID NO.10 1 atgatttcag gcattttagc atccccgggt atcgctttcg gtaaagctct gcttctgaaa 61 gaagacgaaa ttgtcattga ccggaaaaaa atttctgccg accaggttga tcaggaagtt 121 gaacgttttc tgagcggtcg tgccaaggca tcagcccagc tggaaacgat caaaacgaaa 181 gctggtgaaa cgttcggtga agaaaaagaa gccatctttg aagggcatat tatgctgctc 241 gaagatgagg agctggagca ggaaatcata gccctgatta aagataaaca catgacagct 301 gacgcagctg ctcatgaagt tatcgaaggt caggcttctg ccctggaaga gctggatgat 361 gaatacctga aagaacgtgc ggctgacgta cgtgatatcg gtaagcgcct gctgcgcaac 421 atcctgggcc tgaagattat cgacctgagc gccattcagg atgaagtcat tctggttgcc 481 gctgacctga caccgtccga aaccgcacag ctgaacctga agaaggtgct gggtttcatc 541 accgacgcgg gtggccgtac ttcccacacc tctatcatgg cgcgttctct ggaactgcct 601 gctatcgtgg gtaccggtag cgtcacctct caggtgaaaa atgacgacta tctgattctg 661 gatgccgtaa ataatcaggt ttacgtcaat ccaaccaacg aagttattga taaaatgcgc 721 gctgttcagg agcaagtggc ttctgaaaaa gcagagcttg ctaaactgaa agatctgcca 781 gctattacgc tggacggtca ccaagtagaa gtatgcgcta acattggtac ggttcgtgac 841 gttgaaggtg cagagcgtaa cggcgctgaa ggcgttggtc tgtatcgtac tgagttcctg 901 ttcatggacc gcgacgcgct gcccactgaa gaagaacagt ttgctgctta caaagcagtg 961 gctgaagcgt gtggctcgca ggcggttatc gttcgtacca tggacatcgg cggcgacaaa 1021 gagctgccat acatgaactt cccgaaagaa gagaacccgt tcctcggctg gcgcgctatc 1081 cgtatcgcaa tggatcgtaa agagatcctg cgcgatcagc tccgcgctat cctgcgtgcc 1141 tcggctttcg gtaaattgcg cattatgttc ccgatgatca tctctgttga agaagtgcgt 1201 gcactgcgca aagagatcga aatctacaaa caggaactgc gcgacgaagg taaagcgttt 1261 gacgagtcaa ttgaaatcgg cgtaatggtg gaaacaccgg ctgccgcaac aattgcacgt 1321 catttagcca aagaagttga tttctttagt atcggcacca atgatttaac gcagtacact 1381 ctggcagttg accgtggtaa tgatatgatt tcacaccttt accagccaat gtcaccgtcc 1441 gtgctgaact tgatcaagca agttattgat gcttctcatg ctgaaggcaa atggactggc 1501 atgtgtggtg agcttgctgg cgatgaacgt gctacacttc tgttgctggg gatgggtctg 1561 gacgaattct ctatgagcgc catttctatc ccgcgcatta agaagattat ccgtaacacg 1621 aacttcgaag atgcgaaggt gttagcagag caggctcttg ctcaaccgac aacggacgag 1681 ttaatgacgc tggttaacaa gttcattgaa gaaaaaacaa tctgctaa MtdE anaerobic multidrug efflux transporter SEQUENCE ID NO.11. 1 atgaacagaa gaagaaagct gttaataccg ttgttattct gcggcgcgat gctcaccgcc 61 tgcgatgaca aatcggcgga aaacaccgcc gccatgacgc ctgaggtcgg tgtcgtcaca 121 ctctcccctg ggtcggtcaa tgtgttgagc gaattgcccg gtagaaccgt tccttatgaa 181 gttgccgaga tacgtcccca ggtgggcggt attatcatta aacgcaactt tatcgaaggc 241 gataaagtga accagggcga ttcgctgtat cagattgatc ctgcaccttt acaggccgag 301 ctaaactccg ccaaaggctc gctggcgaaa gcgctctcta ccgccagcaa tgcccgcatc 361 acctttaacc gccaggcatc gttgctgaag accaactacg ttagccgtca ggattacgac 421 accgcgcgca cccagttgaa tgaagcagaa gccaatgtca ccgtcgccaa agcggctgtt 481 gaacaggcga cgatcaatct gcaatacgcg aatgtcacct cgccgattac gggcgtcagc 541 gggaaatcgt cggtgaccgt cggcgcactc gttaccgcta atcaggcaga ttcgctggtt 601 accgtacaac gtctggaccc gatttatgtc gatctcacgc agtcggtgca agatttctta 661 cgcatgaaag aagaggtcgc cagtgggcaa atcaaacagg ttcagggcag tacgccagta 721 cagctcaatc tggaaaatgg taaacgttac agccagaccg gcacgctgaa attctccgac 781 ccgacggttg atgaaaccac gggctccgtg acgttacggg cgattttccc caacccaaat 841 ggtgacttgc tgcctggcat gtatgtcacg gcattagtgg atgaaggtag ccgccagaat 901 gtattactgg tgccgcagga aggcgtcacc cacaacgccc aaggtaaagc aacggcgctc 961 attctggata aagacgatgt cgtgaagcta cgcgaaattg aagccagcaa agccatcggc 1021 gaccagtggg ttgtcacctc tggcttgcag gctggcgatc gggtgatcgt ttccggtttg 1081 caacgcattc gtccgggtat caaagcacga gcaatttcct ccagccagga aaacgccagc 1141 accgaatcga aacaataa Putative periplasmic binding transport protein SEQUENCE ID NO.12. 1 atgaaattag cacatctggg acgtcaggca ttgatgggtg tgatggccgt agcgctgatt 61 gcgggcatga gcgttaaaag ttttgcagat gaaggtctgc ttaataaagt taaagagcgc 121 ggcacgctgc tggtagggct ggaaggtact tatccgccgt tcagttttca gggggatgac 181 ggcaaattaa ccggttttga agtggaattt gcccaacagc tggcaaaaca tcttggcgtt 241 gaggcgtcac taaaaccgac caaatgggac ggtatgctgg cgtcgctgga ctctaaacgt 301 attgatgtgg tgattaatca ggtcaccatt tctgatgagc gcaagaaaaa atacgatttc 361 tcaaccccgt acaccatttc tggtattcag gcgctggtga aaaaaggtaa cgaaggcacc 421 attaaaacag ccgatgatct gaaaggcaaa aaagtggggg tcggtctggg caccaactat 481 gaagagtggc tgcggcagaa tgttcagggc gtcgatgtgc gtacctatga tgatgacccg 541 accaaatatc aggatctgcg cgtagggcgt atcgatgcga tcctcgttga tcgtctggcg 601 gcgctggatc tggtgaagaa aaccaacgat acgctggcag taaccggtga agcattctcc 661 cgtcaggagt ctggcgtggc gctgcgtaaa ggaaatgaag acctgctgaa agcagtgaat 721 gatgcaattg cggaaatgca aaaagacggc actttgcaag ccctttccga aaaatggttt 781 ggtgctgatg tgaccaaata a Notably, the invention provides compositions or vaccines comprising at least one immunogen of the invention selected from TerD, YiaF, GlnH, PPP, MdtE and putative periplasmic binding transport protein, immunogens. In an embodiment, the composition or vaccine of the invention comprises at least two immunogens. In an embodiment, the at least two immunogens selected are TerD and YiaF. Immunogens. In an embodiment, the at least two immunogens selected are TerD and GlnH immunogens. In an embodiment, the at least two immunogens selected are TerD and PPP immunogens. In an embodiment, the at least two immunogens selected are TerD and MdtE immunogens. In an embodiment, the at least two immunogens selected are TerD and putative periplasmic binding transport protein immunogens. In an embodiment, the at least two immunogens selected are YiaF and GlnH immunogens. In an embodiment, the at least two immunogens selected YiaF and PPP immunogens. In an embodiment, the at least two immunogens selected YiaF and MdtE immunogens. In an embodiment, the at least two immunogens selected are YiaF and putative periplasmic binding transport protein immunogens. In an embodiment, the at least two immunogens selected are GlnH and PPP immunogens. In an embodiment, the at least two immunogens selected are GlnH and MdtE immunogens. In an embodiment, the at least two immunogens selected are GlnH and putative periplasmic binding transport protein, immunogens. In an embodiment, the at least two immunogens selected are PPP and MdtE immunogens. In an embodiment, the at least two immunogens selected are PPP and putative periplasmic binding transport protein, immunogens. In an embodiment, the composition or vaccine of the invention comprises at least three immunogens. In an embodiment, the at least three two immunogens selected are TerD and YiaF and GlnH immunogens, or TerD and YiaF and PPP immunogens, or TerD and YiaF and MdtE immunogens, or TerD and YiaF and putative periplasmic binding transport protein immunogens. In an embodiment, the at least three immunogens selected TerD and GlnH and PPP immunogens, or TerD and GlnH and MdtE immunogens, or TerD and GlnH and putative periplasmic binding transport protein immunogens. In an embodiment, the at least three immunogens selected are TerD and PPP and MdtE immunogens, or TerD and PPP and putative periplasmic binding transport protein immunogens. In an embodiment, the at least three immunogens selected are TerD and MdtE and putative periplasmic binding transport protein immunogens. In an embodiment, the at least three immunogens selected are YiaF and GlnH and PPP immunogens, or YiaF and GlnH and MdtE immunogens, or YiaF and GlnH and putative periplasmic binding transport protein, immunogens. In an embodiment, the at least three immunogens selected are YiaF and PPP and MdtE immunogens, or YiaF and PPP and putative periplasmic binding transport protein, immunogens. In an embodiment, the at least three immunogens selected are YiaF and MdtE and putative periplasmic binding transport protein, immunogens. In an embodiment, the at least three immunogens selected are GlnH and PPP and MdtE immunogens, or GlnH and PPP and putative periplasmic binding transport protein, immunogens. In an embodiment, the at least three immunogens selected are GlnH and MdtE and putative periplasmic binding transport protein, immunogens. In an embodiment, the at least three immunogens selected are PPP and MdtE and putative periplasmic binding transport protein, immunogens. In an embodiment, the composition or vaccine of the invention comprises at least four immunogens. In an embodiment, the at least four immunogens selected are TerD, YiaF, GlnH and PPP immunogens, or TerD, YiaF, GlnH and MdtE immunogens, or TerD, YiaF, GlnH and putative periplasmic binding transport protein, immunogens. In an embodiment, the at least four TerD, YiaF, PPP and MdtE immunogens, or TerD, YiaF, MdtE and putative periplasmic binding transport protein, immunogens. In an embodiment, the at least four immunogens selected TerD, GlnH, PPP and MdtE immunogens, or TerD, GlnH, PPP and putative periplasmic binding transport protein, immunogens. In an embodiment, the at least four immunogens selected are TerD, GlnH and MdtE and putative periplasmic binding transport protein, immunogens. In an embodiment, the at least four immunogens selected are YiaF, GlnH, PPP and MdtE immunogens, or YiaF, GlnH, PPP and putative periplasmic binding transport protein, immunogens. In an embodiment, the at least four immunogens are YiaF, GlnH, MdtE and putative periplasmic binding transport protein immunogen. In an embodiment, the at least four immunogens selected are YiaF, PPP, MdtE and putative periplasmic binding transport protein, immunogens. In an embodiment, the at least four immunogens selected are YiaF, PPP and MdtE and putative periplasmic binding transport protein immunogens. In an embodiment, the at least four immunogens selected are GlnH, PPP, MdtE and putative periplasmic binding transport protein immunogens. In an embodiment, the at least five immunogens selected are TerD, YiaF, GlnH, PPP and MdtE immunogens, or TerD, YiaF, GlnH, PPP and putative periplasmic binding transport protein immunogens. In an embodiment, the at least five immunogens selected are TerD, YiaF, GlnH, MdtE and putative periplasmic binding transport protein immunogens. In an embodiment, the at least five immunogens selected are TerD, YiaF, PPP, MdtE and putative periplasmic binding transport protein immunogens. In an embodiment, the at least five immunogens selected are TerD, GlnH, PPP, MdtE and putative periplasmic binding transport protein, immunogens. In an embodiment, the at least five immunogens selected are YiaF, GlnH, PPP, MdtE and periplasmic binding transport protein immunogens. In an embodiment, the at least six immunogens selected are TerD, YiaF, GlnH, PPP and MdtE and periplasmic binding transport protein immunogen. In an embodiment, the vaccine or composition of the invention comprises seven immunogens. It will be appreciated that in the embodiments disclosed above, the composition or vaccine may comprise a nucleotide encoding the immunogen, or an mRNA encoding the immunogen instead of the immunogen itself. In such an embodiment, the vaccine may be a DNA vaccine. It may be an adenoviral vector vaccine which comprise one or more nucleotide sequences encoding an immunogen of the invention. In such an embodiment, the vaccine may be an mRNA vaccine. The vaccine or composition of the invention may comprise a combination of immunogenic portions. The Glutamine binding periplasmic protein (GlnH) is a cytoplasmic protein, predominately associated with transport function. The GlnH protein is involved in the glutamine transport system (GlnHPQ) and belongs to a larger superfamily of ATP-binding cassette (ABC) transporters specifically from the bacterial extracellular solute-binding proteins (SBP) cluster. GlnH is responsible for the active transport ofL-glutamine across the cytoplasmic membrane. The vaccine may have one or more adjuvants. Typically, the adjuvant is one that induces a T cell and B cell response, e.g., the CAF series, such as CAF-01. It will be appreciated that such adjuvants are known in the art. The invention also provides a method of diagnosis of VTEC infection in a mammal. The method comprises assaying a sample from the mammal for the presence of one or more proteins of the invention (or a gene encoding the protein of the invention). The method may involve assaying or detecting for one or more antibodies that are specific to one or more proteins of the invention. In this way, the presence or absence of one or more proteins of the invention may be indirectly determined. Presence of said one or more proteins in same sample is indicative of VTEC infection. Absence of said one or more proteins in the sample indicates the absence of VTEC infection. In a notable embodiment, the proteins are selected from FkpA, GlnH and YiaF. Presence of at least one of these proteins in the sample is indicative of VTEC infection in the mammal. In an embodiment, the method comprises assaying a sample for the presence of two proteins (or gene encoding the protein). The at least two proteins may be FkpA and GlnH, or FkpA and YiaF, or GlnH and YiaF. In an embodiment, the method comprises assaying a sample of the presence of three proteins (or genes encoding the protein), said three proteins being FkpA, GlnH, and YiaF. In an embodiment, the strain to be detected is a strain common in the United States of America, particularly California. In this example, the subject is one residing in this jurisdiction. In an embodiment, the strain to be detected is a strain common in Europe, particularly in Ireland. In this example, the subject is one residing in this jurisdiction. In an embodiment, the proteins are selected from FkpA, GlnH, YiaF and TerD. This embodiment is particularly useful for strains that are common in a strain common in the United States of America, particularly California. Suitably, the determination system may be selected from an immunohistochemical detection a Western Blot, Enzyme-linked Immunosorbent Assay (ELISA) a Northern Blot, a Southern Blot, quantitative polymerase chain reaction (PCR), reverse transcriptase PCR (RT-PCR), quantitative real time RT-PCR (qRTPCR), an enzyme-linked immunosorbent assay (ELISA), protein determination on polyacrylamide gels, and such methods known to those skilled in the art. Ideally, the system is PCR, or RT-PCR. In an embodiment, the method of diagnosis of the invention detects one or more antibodies specific to one or more of the proteins of the current invention. In this method, detection could be by any known means, e.g. ELISA from a blood or saliva sample from the subject, or by using a lateral flow device. The antibodies are developed in the subject and specifically bind to the protein antigens as evidence of infection or colonisation. The method of diagnosing may further comprise a method of treating the infection once diagnosed. The method of treatment may be any known method. It may be a method of treatment as disclosed herein. FKPB-type peptidyl-prolyl cis-trans isomerase FkpA is a PPIase which are routinely responsible for accelerating the folding of proteins. FkpA has a molecular weight of 28.9 kDa with an isoelectric point of 8.39. This protein’s structure is made up of two domains; the N- terminal domain consisting of three alpha helices responsible for its chaperone activity and, the C-terminal, made up primarily of anti-parallel beta pleated sheets, where the FK506 binding domain resides contributing to its PPIase activity. FkpA is normally expressed under stressful conditions including the build-up of misfolded protein aggregates or in response to heat shock. For example, FkpA has previously been shown to play a critical role in the survival of Cronobacter, the causative agent of sepsis and meningitis in children. Furthermore, it has been shown to moderate starvation stress response in Salmonella species as well as conferring resistance to temperature and stress (REF). In previous studies, FkpA has been shown to be a chaperone involved in safeguarding unfolded outer membrane proteins (uOMPs) irrespective of lacking the obvious cage-like structures that are usually associated with uOMP binding. The mechanism by which FkpA binds to uOMP’s to prevent aggregation is still unelucidated. FkpA NCBI sequence ID: WP_000838261.1. NP_312225.1. The term FkpA encompasses this protein and therapeutically effective variants that share at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with SEQUENCE ID NO: 13. The amino acid sequence of FklA expressed by VTEC is provided in SEQUENCE ID NO.13. The nucleic acid sequence of FkpA is provided in SEQUENCE ID NO 14. (FkpA) FKBP type peptidyl-prolyl cis-trans isomerase amino acid sequence: SEQUENCE ID NO.13 MKSLFKVTLLATTMAVALHAPITFAAEAAKPATTADSKAAFKNDDQKSAYALGASLGRYM ENSLKEQEKLGIKLDKDQLIAGVQDAFADKSKLSDQEIEQTLQAFEARVKSSAQAKMEKD AADNEAKGKEYREKFAKEKGVKTSSTGLVYQVVEAGKGEAPKDSDTVVVNYKGTLIDGKE FDNSYTRGEPLSFRLDGVIPGWTEGLKNIKKGGKIKLVIPPELAYGKAGVPGIPPNSTLV FDVELLDVKPAPKADAKPEADAKAADSAKK (FkpA) FKBP type peptidyl-prolyl cis-trans isomerase nucleotide sequence: SEQUENCE ID NO.14 1 atgaaatcac tgtttaaagt aacgctgctg gcgaccacaa tggccgttgc cttgcatgca 61 ccaatcactt ttgctgctga agctgcaaaa cctgctacaa ctgctgacag caaagcagcg 121 ttcaaaaatg acgatcagaa atcagcttat gcactgggtg cctcgctggg tcgttacatg 181 gaaaactctc taaaagaaca agaaaaactg ggcatcaaac tggataaaga tcagctgatc 241 gctggtgttc aggatgcatt tgctgataag agcaaactct ccgaccaaga gatcgaacag 301 actctgcaag cattcgaagc tcgcgtgaag tcttctgctc aggcgaagat ggaaaaagac 361 gcggctgata acgaagcaaa aggtaaagag taccgcgaga aatttgccaa agagaaaggt 421 gtgaaaacct cttccactgg tctggtttat caggtagtag aagccggtaa aggcgaagca 481 ccgaaagaca gcgatactgt tgtcgtgaac tacaaaggta cgctgatcga cggtaaagag 541 ttcgacaact cttacacccg tggtgaaccg ctctctttcc gtctggacgg tgttatcccg 601 ggttggacag aaggtctgaa gaacatcaag aaaggcggta agatcaaact ggttattcca 661 ccagaactgg cttacggcaa agcgggtgtt ccggggatcc caccgaattc taccctggtg 721 tttgacgtag agctgctgga tgtgaaacca gcgccgaagg ctgatgcaaa gccggaagct 781 gatgcgaaag ccgcagattc tgctaaaaaa taa An aspect of the invention provides a method for treating or preventing VTEC infection in a mammal, the method comprising, assaying a sample from the mammal for the presence of one or more proteins of the invention (or a gene encoding the protein of the invention) to determine the presence or absence of VTEC infection as per the method of the invention, administering treatment to the subject if determined to have a VTEC infection. A method of identifying a subject that is suitable for treatment of VTEC infection, the method comprising, assaying a sample from the mammal for the presence of one or more proteins of the invention (or a gene encoding the protein of the invention) to determine the presence or absence of VTEC infection as per the method of the invention, wherein the presence of one or more proteins is indicative of VTEC infection and that the subject is suitable for treatment. In an aspect of the invention, there is provided a system for obtaining data from at least one test sample obtained from at least one individual, the system comprising: a determination module configured to receive at least one test sample and perform at least one test analysis on the test sample to assay for expression of at one or more of TerD, YiaF, GlnH, PPP, MdtE and putative periplasmic binding transport protein, optionally, a storage system for storing expression data generated by the determination module; and a display module for displaying a content based in part on the data output from said determination module, wherein the content comprises a signal indicative of the proteins. Embodiments of the invention also provide for systems (and computer readable media for causing computer systems) to perform the method(s) of the invention. In one embodiment of the invention, there is provided a system for obtaining data from at least one test sample obtained from at least one individual, the system comprising: a determination module configured to receive at least one test sample and perform at least one test analysis on the test sample to assay for presence of at least one protein selected from TerD, YiaF, GlnH, PPP, MdtE and putative periplasmic binding transport protein, optionally, a storage system for storing expression data generated by the determination module; and a display module for displaying a content based in part on the data output from said determination module, wherein the content comprises a signal indicative of the presence of at least one protein. However, it should be understood that the modules / systems need not correspond to discreet blocks of code and the described functions can be carried out by the execution of various code portions stored on various media and executed at various times. Furthermore, it should be appreciated that the modules / systems may perform other functions, thus the modules are not limited to having any particular functions or set of functions. The display module displays a content based in part on the data from the correlation system, the content optionally comprising a signal indicative of the result. The comparison module may be configured using existing commercially-available or freely-available software for comparing patterns, staining, and may be optimized for particular data comparisons that are conducted. Suitably, the determination system may be selected from an immunohistochemical detection apparatus, a Western Blot, a Northern Blot, a Southern Blot, an enzyme-linked immunosorbent assay (ELISA), a lateral flow device, protein determination on polyacrylamide gels, and such methods known to those skilled in the art. In one embodiment of the invention, the content is displayed on a computer monitor. In one embodiment of the invention, the content is displayed through printable media. The display module can be any suitable device configured to receive from a computer and display computer readable information to a user. Non-limiting examples include, for example, general- purpose computers such as those based on Intel PENTIUM-type processor, 30 Motorola PowerPC, Sun UltraSPARC, Hewlett-Packard PA-RISC processors, any of a variety of processors available from Advanced Micro Devices (AMD) of Sunnyvale, California, or any other type of processor, visual display devices such as flat panel displays, cathode ray tubes and the like, as well as computer printers of various types. In one embodiment, a World Wide Web browser is used for providing a user interface for display of the content based on the comparison result. It should be understood that other modules of the invention can be adapted to have a web browser interface. Through the Web browser, a user may construct requests for retrieving data from the comparison module. Thus, the user will typically point and click to user interface elements such as buttons, pull down menus, scroll bars and the like conventionally employed in graphical user interfaces. Basic computational biology methods are known to those of ordinary skill in the art and are described in, for example, Setubal and Meidanis et al., Introduction to Computational Biology Methods (PWS Publishing Company, Boston, 1997); Salzberg, Searles, Kasif, (Ed.), Computational Methods in Molecular Biology, (Elsevier, Amsterdam, 1998); Rashidi and Buehler, Bioinformatics Basics: Application in Biological Science and Medicine (CRC Press, London, 2000) and Ouelette and Bzevanis Bioinformatics: A Practical Guide for Analysis of Gene and Proteins (Wiley & Sons, Inc., 2nd ed., 2001). The determination system has computer executable instructions to provide results in computer readable form. The determination system can comprise any system for proteins. The information determined in the determination system can be read by the storage device. As used herein the “storage device” is intended to include any suitable computing or processing apparatus or other device configured or adapted for storing data or information. Examples of an electronic apparatus suitable for use with the present invention include a stand-alone computing apparatus, data telecommunications networks, including local area networks (LAN), wide area networks (WAN), Internet, Intranet, and Extranet, and local and distributed computer processing systems. Storage devices also include, but are not limited to: magnetic storage media, such as floppy discs, hard disc storage media, magnetic tape, optical storage media such as CD-ROM, DVD, electronic storage media such as RAM, ROM, EPROM, EEPROM and the like, general hard disks and hybrids of these categories such as magnetic / optical storage media. The storage device is adapted or configured for having recorded thereon nucleic acid sequence information. Such information may be provided in digital form that can be transmitted and read electronically, e.g., via the Internet, on diskette, via USB (universal serial bus) or via any other suitable mode of communication. The methods described herein therefore provide for systems (and computer readable media for causing computer systems) to perform methods as described in the Statements of Invention above. Systems and computer readable media described herein are merely illustrative embodiments of the invention for performing methods of diagnosis in an individual, and are not intended to limit the scope of the invention. Variations of the systems and computer readable media described herein are possible and are intended to fall within the scope of the invention. The modules of the machine, or those used in the computer readable medium, may assume numerous configurations. For example, function may be provided on a single machine or distributed over multiple machines. The invention will now be described with reference to specific Examples. These are merely exemplary and for illustrative purposes only: they are not intended to be limiting in any way to the scope of the monopoly claimed or to the invention described. These examples constitute the best mode currently contemplated for practicing the invention. EXAMPLES EXAMPLE 1 Identification of VTEC antigens METHODS Using a proteomic platform whereby 2D electrophoresis is used to identify outer membrane proteins, 11 potential bacterial adhesins exclusive to VTEC strain O157 were identified on their ability to interact with gastrointestinal cells in vitro. Bacterial strains Three strains were used in this study: ^ E .coli O157:H7 strain NCTC 12900 ^ non-O157 VTEC O2:H27 strain M25 ^ Commensal E. coli strain HS Human Cell lines and maintenance. Two human gastrointestinal cell lines were used, human colorectal adenocarcinoma cells (HT29) and Human colon carcinoma (CaCo-2). HT-29 cells were routinely grown were maintained in McCoy’s 5a media supplemented with 10 % v / v foetal bovine serum (FBS) (Sigma Aldrich), 1 % v / v penicillin / streptomycin and 1 % L-glutamine. The Caco-2 cells were maintained in Dulbecco’s modified eagle’s medium (DMEM) supplemented with 10 % v / v FBS, 1 % v / v penicillin / streptomycin, 1 % L-glutamine and 1 % v / v non-essential amino acids. Outer Membrane Protein preparation and quantification Overnight cultures of bacterial strains were harvested by centrifugation at 5200 rpm for 10 minutes at 4 °C and then resuspended in lysis buffer containing 0.01 M 4-(2-hydroxyethyl)-1- piperazineethanesulfonic acid (HEPES) solution, 800 µl protease EDTA-free inhibitor cocktail and 10 mg / ml lysozyme and incubated at 37 °C for 2 hours at 80 rpm. After incubation, 4 % (v / v) triton X-100 was added followed by bead beating on ice for 2 mins at 5 mins intervals for one hour. The supernatant was separated from cell debris and glass beads by centrifugation at 5200 rpm for 10 minutes at 4 °C and maintained on ice between each experimental step. The supernatants were further centrifuged at 12,000 x g using a Sorvall RC-6 plus (rotor SS- 34) for 10 mins at 4 °C to remove cell debris. The supernatant was transferred to a fresh tube and treated with 15 mL 2 % Sarkosyl for 30 minutes at 25 degrees and ultracentrifuged at 20,500 x g for 80 minutes. The supernatant was discarded, and the pellet resuspended in 1 ml dH2O for a second ultracentrugation step at 20,500 x g and the proteins in the pellet were solubilised by incubation with 15 mls 2 % Sarkosyl (N-Lauroylsarcosine sodium salt) at 25 °C (Montero, D. et al, 2014). After solubilisation, ultracentrifugation was carried out at 20,500 x g for 80 minutes at 4 °C. The OMP pellets were resuspended in 1 ml filtered deionised water. Aliquots of 100 µl of OMP preparation were removed to estimate the protein concentration using Bicinchoninic acid (BCA) test kit. A second ultracentrifugation step was carried out on the remaining 900 µl at 20,500 x g for 50 minutes at 4 °C. The OMP pellets were resuspended in 1 ml 2-D lysis buffer containing 8 M urea, 2 M thiourea, 4 % 3-((3- Cholamidopropyl)dimethylammonio)-1-Propanesulfonic acid (CHAPS), 1 % triton X-100, 10 mM Tris Base, 65 mM dithiothreitol (DTT) and 0.8 % Immobilised pH gradient (IPG) buffer in ultra-pure water. Protein separation by 2-D gel electrophoresis OMP preparations for each strain were solubilised for isoelectric focusing (IEF) in rehydration buffer to a total volume of 125 µl, containing 8 M urea, 2 M thiourea, 4 % CHAPS, 1 % Triton X-100, 10 mM Tris base, 65 mM DTT and 0.8 % (v / v) IPG buffer (pH 3-11NL) with a trace of bromophenol blue. IPG strips (pH 3-11) NL of 7 cm were rehydrated overnight with 125 µl of rehydration solution containing 200 µg of proteins. IEF was carried for a total of 3 hours using the following conditions: 500 V for 30 minutes, 1000 V for 30 minutes and 5000 V for 2 hours. Following IEF, IPG strips were incubated at room temperature for 15 minutes in equilibration buffer containing 2 % DTT, 30 % glycerol, 2 % SDS, 6 M urea and 50 mM Tris. Alkylation of proteins was then carried out for an additional 15 minutes in the same buffer containing 2.5 % iodoacetamide instead of DTT. IPG strips were placed on 12 % SDS-PAGE gels and sealed with agarose containing a trace of bromophenol blue. Separation was carried out for 20 minutes at 80 V followed by an additional 90 minutes at an increased voltage of 120 V. The polyacrylamide gels were equilibrated in transfer buffer for 15 minutes. Immoblion-P transfer membranes were activated by successive submersions in methanol, water, and transfer buffer and the protein transferred using a semi-dry transfer cell at 20 V for 2 hours. Gastrointestinal epithelial cell probed blots Proteins involved in intestinal cell attachment were detected using a modified method from McClean et al (2016). After protein transfer, the membranes were blocked overnight at 4 °C with 5 % BSA and 3 % Marvel in PBS with rotation (60 rpm). Human intestinal epithelial cells, either CaCo-2 or HT-29 were scraped from T75 culture flasks and resuspended in PBS (10 mls containing 1 x 107cells). The intestinal epithelial cells were incubated with the membranes for 4 hours at 37 °C with gentle agitation (60 rpm). The membranes were then rinsed with 20 ml of PBS, before the interacting epithelial cells were fixed with 3 % paraformaldehyde in PBS for 10 minutes. Bound cells were detected by incubating the membrane with an anti-epithelial cell antibody (MERCK) (1:1000 in 5 % (w / v) BSA and 0.5 % (v / v) PBS-T) overnight at 4 °C with end-to-end rotation. The membranes were then washed three times with 0.5 % (v / v) PBS- T. This was followed by the addition of a secondary HRP conjugated anti-mouse antibody at a 1:36,000 dilution in 5 % BSA and 0.5 % PBS-T. The secondary HRP antibody was incubated for 1 hour at room temperature with end-to-end rotation. The membranes were then subsequently washed 5 times with 0.5 % PBS-T before chemiluminescence detection with luminol reagent, incubated for 5 minutes at room temperature, followed by exposing the film for 20-30 minutes. Tryptic digestion of protein samples and LC / MS analysis The protein spots were matched between blot and Coomassie blue-stained 2D gel and were excised from 2-D gels and destained using 100 mM ammonium bicarbonate / acetonitrile (1:1, v / v). Tryptic digestion of proteins was performed following the in-gel digestion method described by Shevchenko et al. (2006). Dried proteins were then resuspended in 0.5 % TFA in LC-MS grade water and further purified with zip-tips before vacuum drying and resuspending in 20ul of loading buffer containing 2.5 % Acetonitrile and 0.5 % Acetic acid in LC / MS grade water for LC-MS analysis. RESULTS Identification of proteins involved in gastrointestinal cell attachment. Attachment of the VTEC strain O157 to gastrointestinal cell lines. The 2D gel separation of E. coli O157:H7 membrane proteins showed approximately one hundred and fifty protein spots which were visible after staining with PageBlueTMprotein staining solution (Fig 1). Most spots identified were in the pH 4 – 9 range. Protein spots varied in intensity with some spots that were darker in appearance than others. When a blot prepared in parallel was probed with HT29 cells (Figure 1A), eight clear spots were identified between 20 kDa and 31 kDa as being positive for cellular attachment. The excised proteins were identified by MS as GrpE, Putative tellurium resistance protein TerD, Uncharacterised protein YiaF, Alkyl hydroperoxide reductase C (AhpC), Succinate—CoA ligase [ADP-forming] subunit alpha (SucD), FKBP-type peptidyl-prolyl cis-trans isomerase FkpA and Glutamine binding periplasmic protein (GlnH) (Table 1). An additional six spots were identified on CaCo-2 blots (Figure 1B) in the region of 26 kDa to 64 kDa and these proteins were identified as GrpE, Phosphoglycerate kinase (PgK), Phosphoenolpyruvate-protein phosphotransferase (PPP), Enolase (Eno), FkpA and GlnH. Similar proteins were identified in both blots while others were exclusive to interaction with either HT29 or CaCo-2 cells (Table 2). Attachment of the non-O157 VTEC strain O2:H27 to gastrointestinal cells. The 2D gels separating of E. coli O2:H27 membrane proteins showed approximately between 100 and 150 one hundred and fifty protein spots which were visible after staining with PageBlueTMprotein staining solution. Most spots identified were found to be in the pH 4 – 9 range. Several spots were reproducibly identified between 21 kDa – 50 kDa regions indicating host cell attachment (Table 2). These included two proteins were identified on HT29 probed blots in both pathogenic E. coli strains O157:H7, Enolase and FKBP-type peptidyl-prolyl cis- trans isomerase FkpA (Table 2). Attachment of the commensal E. coli strain HS to gastrointestinal cells. As controls, commensal E. coli strain HS underwent the same analysis. The 2-D gells of the E. coli HS membrane proteins showed approximately fifty protein spots which were visible after staining with PageBlueTMstaining solution. Most spots identified were found in the pH 4 – 7 range. The proteins identified in HT-29-probed blots included Elongation factor Tu (EfTu), and Flagellin (FliC), (Table 2). Only one spot was identified on CaCo-2 blot (Figure 8C) at 60 kDa. Flagellin and was also identified in blots probed CaCo-2 cells (Table 2). Any proteins that were identified in both pathogenic E. coli strains and commensal E. coli HS including Elongation factor Tu, which was excluded from any further analysis (Table 2). Protein ID Protein name Sequence Unique pI m.w Spectr Cell line coverage peptides kDa um % Mill score Escherichia coli O157:H7 strain NCTC 12900 P0AEQ5 Glutamine binding periplasmic 77.8 21 8.44 27.19 358.58 HT29 protein (GlnH) &CaCo2 P65765 FKBP-type peptidyl-prolyl cis- 48.5 15 8.39 28.9 260.58 HT29 trans isomerase FkpA &CaCo-2 Q8X9P9 Putative tellurium resistance 71.8 11 4.69 20.5 218.61 HT29 protein TerD P0AE10 Alkyl hydroperoxide reductase 72.1 12 5.03 20.8 214.97 HT29 C (AhpC) P0ADK2 Uncharacterised protein YiaF 55 7 6.08 25.7 117.7 HT29 Q7ABI1 Protein GrpE 67.5 17 4.68 21.8 258.66 HT29 & CaCo-2 P0AGF1 Succinate—CoA ligase [ADP- 66.4 14 6.32 30.1 247.46 HT29 forming] subunit alpha (SucD) Q8XBL3 Phosphoenolpyruvate-protein 23.1 15 4.78 63.7 323.31 CaCo-2 phosphotransferase (PPP) Q8XD03 Phosphoglycerate kinase (PgK) 33.1 15 4.97 41.13 323.21 CaCo-2 P0A6Q1 Enolase (Eno) 41 22 5.32 45.7 323.31 CaCo-2 Escherichia coli O2:H27 strain M25 P0A6Z0 Chaperone protein DnaK 54.5 29 4.83 69.17 538.11 CaCo-2 P0A6F7 60 kDa chaperonin (GroL) 45.9 16 4.85 57.5 272.95 CaCo-2 P0A6N3 Elongation factor Tu (EfTu) 65.9 20 5.3 43.5 346.98 CaCo-2 P0A6Q1 Enolase (Eno) 71.9 20 5.32 45.7 373.17 CaCo-2 P0C0V1 Periplasmic serine 50.6 25 8.81 49.3 323.21 HT29 endoprotease DegP P65765 FKBP-type peptidyl-prolyl cis- 42.2 14 8.39 28.9 235.16 HT29 trans isomerase FkpA P0AGD5 Superoxide dismutase [Fe] 56.4 7 5.58 21.3 130 HT29 (SodB) Q8XB46 Hyperosmotically inducible 34.8 6 5.95 21.1 120.36 HT29 periplasmic protein (OsmY) Commensal Escherichia coli strain HS Q8XAA9 Outer membrane protein 24.2 8 4.6 41.8 323.31 HT29 assembly factor BamB Q8XDF1 Outer membrane protein 1a 14.9 5 4.64 39.3 139.32 HT29 (Omp1a) P0A6N3 Elongation factor Tu (EfTu) 66 24 5.3 43.5 323.21 HT29 Q8XBP7 Outer membrane channel TolC 13.5 6 5.33 53.98 159.54 HT29 A0A0H3JE39 Oligopeptide transport 27.6 13 5.71 60.97 323.31 HT29 periplasmic binding protein (OppA) P0ADV3 Lipopolysaccharide export 47 14 8.3 20.1 320.57 HT29 system protein (LptA) Q7DBI0 Flagellin (fliC) 2.7 2 4.7 59.9 43.52 HT29 & CaCo-2 Q8XAW6 D-ribose periplasmic binding 67.9 16 6.85 30.9 304.08 HT29 protein (RbsB) Q8X8L3 Uridine phosphorylase (Udp) 83.3 12 5.71 27.3 218.33 HT29 Table 2: LC / MS analysis of E. coli O157:H7, O2:H27 and commensal strain HS proteins involved in gastrointestinal cell attachment. EXAMPLE 2 GlnH and protection against VTEC METHODS Cloning GlnH GlnH primers were designed using BLAST NCIB search of Uniprot ID P0AEQ5 gene name GlnH / ECs0889 against Escherichia coli O157:H7 str. Sakai genome sequence NC_002695.1. The forward primer (CACCATGAAGTCTGTATTAAAAGT (SEQUENCE ID NO 15) was designed specifically to contain the four base pair sequence ‘CACC’ as the start codon for the introduction of a 5’ overhang to allow for directional cloning of the GlnH gene into the pET100 / D-TOPO vector. The reverse primer (TTATTTCGGTTCAGTACCGA) (SEQUENCE ID NO 16) complimented the forward for synthesis of gene of interest producing a gene product 747 base pairs in size. The vector contains a N-terminal 6x-his tag, and its expression is controlled by the presence of a T7 promoter. The amplification of glnH genes were carried out using polymerase chain reaction. PCR products were run on 2% agarose gel electrophoresis and visualised using a gel imager. GlnH expression and purification Overnight cultures (100 ml) containing E. coli BL21 cells transformed with pET-D / Topo vectors containing the GlnH gene were re-inoculated into 2 Litres of LB broth supplemented with 50 ug / ml carbenicillin. Cultures were grown for two hours to mid-log phase at 37 °C with shaking at 200 rpm. After 2 hours, cultures were induced with IPTG at a final concentration of 0.1 mM and grown for an additional 5 hours at 37 °C at 200 rpm. Bacterial cells were pelleted by centrifugation at 5,200 rpm for 10 minutes at 4 °C. The supernatants were discarded, and the cell pellets were resuspended in 100 ml Ni-NTA lysis buffer containing 95 ml Ni-NTA lysis buffer containing 50 mM Tris HCl, 300 mM NaCl, 10 % glycerol and 10 mM Imidazole adjusted to pH 8.8 with 5N NaOH in milli-Q water and one protease inhibitor cocktail tablet and 5 ml lysozyme (0.5 mg / ml). The protein lysate was incubated on ice with mild rotation using a magnetic stirrer for 15 minutes before suspension was sonicated on ice using ten 15 second pulses with 1-minute rest intervals. After sonication, protein samples were ultracentrifuged at 15,000 rpm for 1 hour at 4 °C. Nickel resin (2 ml) was equilibrated by rinsing with milli-Q water followed by Ni-NTA lysis buffer, before supernatant was incubated with the resin overnight at 4 °C with mild rotation using magnetic stirrer. After overnight incubation, the supernatant containing resin was passed through column before being washed with 250 ml wash buffer containing 50 mM Tris HCl, 300 mM NaCl, 10% glycerol and 10 mM imidazole adjusted to pH 8.8 using 5N NaOH in milli-Q water to remove any unwanted proteins present in the lysate. The GlnH protein was eluted using 50 mM Tris HCl, 300 mM NaCl, with either 250 mM Imidazole or 300 mM Imidazole and 10% glycerol adjusted to pH 8.8 with 5N NaOH in Milli- Q water. A total Nine ml of eluent was concentrated to 5.5 ml using Amicon Ultra-cell 3-10K filter by centrifugation at 4,000 rpm for 15-20 minutes. Prior to protein injection, the Size Exclusion (SE) column was equilibrated overnight in protein buffer containing 50 mM Tris HCl, 300 mM NaCl adjusted to pH 8.8 using 5 N NaOH in milli-Q water and filter sterilised and degassed using vacuum. Concentrated protein eluents (5.5 ml) were injected onto a pre- equilibrated Hi load 16 / 60 Superdex 75 size exclusion column. The column flow through was collected in 1.8 ml fractions. High absorbance readings at 280 nm representative of a large single peak on the SE chromatogram represented fractions containing purified GlnH. Aliquots of each fraction (100-200µl) were collected for visualisation on SDS-PAGE and each fraction was pooled together for further analysis. Comparing the effect of induced and uninduced E. coli BL21 recombinant GlnH expressing strains on attachment to gastrointestinal cells in vitro Gastrointestinal cells (either HT29 or CaCo-2) were seeded overnight in 24-well plates at a density of 4 x 105cells / well. The following day, overnight cultures of E. coli BL21 transformed with putative GlnH gene were re-inoculated into 2x 100 ml flasks of fresh LB broth containing 50 ug / ml Carbenicillin and cultured for 2 hours at 37 °C. Induction of GlnH expression was induced in one flask only, by the addition of IPTG, at a final concentration of 1 mM for 3 hours. The remaining culture remained uninduced for 3 hours. The seeded cell media was removed, and cells were washed with fresh media (HT29; McCoy’s / CaCo-2; DMEM) only. After 3 hours, the bacteria were resuspended in the appropriate media depending on the cell line used and added to each well at an MOI of 25:1 (1 x 107CFU / well). To enhance bacterial-cell attachment, 24-well plates were centrifuged at 1,200 rpm for 5 minutes before plates were incubated at 37 °C and 5 % CO2 for 30 minutes. After incubation, wells were washed four times in sterile PBS before bacteria infected cells were detached from the well plate by incubation in lysis buffer (125 µl Triton X-100 in 50 ml PBS) for 20 minutes at room temperature. Wells were scraped using fresh pipette tips and the contents of each well were serially diluted and plated onto LB agar supplemented with 50 ug / ml Carbenicillin. Plates were incubated overnight at 37 °C and the number of bacterial cells adhering were determined by plate counting. Ethics statement All work involving animals was approved by University College Dublin Ethic Committee (AREC-18-30-McClean), and mice were maintained according to the regulations of the Health Products Regulatory Authority (HPRA) (Directive 2010 / 63 / EU and Irish Statutory Instrument 543 of 2012) with the authorisation number AE18982 / P156. Three-dose subcutaneous (s.c.) immunisation with GlnH and bacterial challenge in BALB / c mice. Groups 6-8-week-old BALB / c mice (5 mice per group) were used to evaluate the protective efficacy of GlnH from Charles River, UK.. The four groups of BALB / c mice were immunised with either 10 µg or 50 µg of endotoxin free GlnH in buffer mixed 1:1 alum, alum alone or PBS alone in a total volume of 100 µl on day 0, followed by two booster immunisations on days 14 and 28. Subcutaneous administration involved two 50 µl dosages on both sides of the mouse stomach to maximise uptake and immune response. Blood was collected from each mouse on day 35 for serological analysis of the immune response against GlnH immunisation via submandibular vein. The food from each mice cage was restricted on Day 41, twelve hours before O157 the challenge. Mice from each group were challenged on Day 42 – Day 48. Two-dose subcutaneous (s.c.) immunisation with 10 ug GlnH and bacterial challenge in female BALB / c mice. Groups of 6-8-week-old female BALB / c mice (6 mice per group) were used to evaluate the protective efficacy of GlnH from Charles River, UK., were grouped at random. All mice were acclimatized to their new environment for one week before immunisation trials commenced. Using a 25G needle, four groups of BALB / c female mice (n=6) were immunised with 10 µg of endotoxin free GlnH in combination with either 1:1 SAS or alum, or SAS or alum alone in a total volume of 100 µl with buffer on day 0, followed by one booster immunisations on day 14. Blood was collected from each mouse on day 42 for serological analysis of the immune response against GlnH immunisation via submandibular vein. The food from each mice cage was restricted on Day 48, twelve hours before O157 the challenge. Mice from each group were challenged on Day 49 – Day 55. Detection of protein-specific IgG antibodies raised in response to GlnH immunisation using indirect ELISA. Ninetysix well plates were coated in 100 µl of coating buffer containing 0.2 M sodium carbonate pH 9.6 and 0.5 µg / ml of purified protein sample. Plates were covered and incubated overnight at 4 °C. The next day, coating buffer was removed from each well and plates were washed 3 times with 300 µl of 1 X PBS with 0.05% Tween-20 using a plate washer. After washing, wells were blocked in 100 µl blocking buffer containing 1 X PBS and 1 % FBS for 1 hour at room temperature. After incubation, the blocking buffer was removed, and fresh blocking buffer was applied to all wells (100 µl / well), except for the top row on each 96 well plate. A different volume of blocking buffer (120 µl / well) was added to each well in row 1 before 5 µl of each serum sample were added to each well in triplicate. The sera were mixed and serially diluted from rows 1-8 using a multichannel pipette (25 µl). After serial dilution, plates were covered and incubated for two hours at room temperature. The well contents were removed, and wells were washed 3 times in 300 µl / well 1 X PBS with 0.05 % Tween 20 using a plate washer. The wells were incubated in 100 µl of Anti-mouse IgG total-HRP secondary antibody at a concentration of 1:5000 in 1 X PBS and 1 % FBS at room temperature for 45- 60 minutes. The antibody solution was removed, and the plates were washed again 3 times with 300 µl 1 X PBS 0.05% Tween 20 followed by two additional washes containing 400 µl / well of 1 X PBS, to avoid potential interference from Tween 20. Plates were dried by tapping on a paper towel after washing in both wash solutions. The TMB substrate solution (100 µl) was added to each well and the plates were incubated at room temperature until a colour change was observed at which time reactions ceased using 100 µl / well of 2 M Sulfuric acid. Plates were read at an absorbance of 450 nm within 30 minutes. Prototype strain Vtx 1 and Vtx 2 negative E. coli O157 strain NCTC 12900 Nalr resistant. Shiga toxin negative E. coli O157 prototype strain NCTC 12900 was made resistant to Nalidixic acid sodium salt (Sigma Aldrich, product code N4382-5G) by passage on SMAC agar supplemented with 15 ug / ml nalidixic acid and designated Vtx negative E. coli O157 prototype strain NCTC12900 Nalr(La Ragione, R. M. et al, 2005). NCTC12900 Nalrbacterial stocks were made from inoculation of colonies positive for Nalrresistance into 10 mls of LB broth supplemented with 15 ug / ml Nalidixic acid sodium salt and incubated overnight at 37 °C at 200 rpm.5 mls of preculture was re-inoculated into 100 ml LB broth supplemented with 15 ug / ml nalidixic acid sodium salt and grown to an optical density (OD) 0.4-0.8. Cells were pelleted by centrifugation at 5,200 rpm for 10 minutes before being resuspended in LB broth containing 20 % glycerol. Stocks were stored at – 80 °C until needed. Daily course of O157 infection in mice by enumerating the number of bacteria shed by faecal monitoring Two 0.1 g samples of faecal pellets were collected daily during monitoring from each treatment group’s cage post bacterial challenge. O157 infected stool samples were homogenised by vigorous vortexing in 1 ml PBS before being left stand to separate debris by sedimentation. Faecal homogenates were serially diluted in Ringer’s solution to 10-6and plated (50 uL) on MacConkey agar with Sorbitol supplemented with 15 µg / ml Nalidixic acid. Plates were counted on the following day representative of the number of bacteria shed daily in faeces from O157 infected mice. Determining the level of O157 colonisation in the GI tract of individual BALB / c mice Prior to euthanasia, mice were weighed, monitored and faecal pellets collected from each treatment cage. All BALB / c mice were sacrificed by carbon dioxide exposure for 9 minutes 7 days post challenge. Once death by cervical dislocation was confirmed, the organs were dissected from individual mice and transferred into 5 ml sterile PBS. Mouse tissue samples were measured (cm) and weighed (g) and placed into 1.5 ml appropriate tissue lyser cryovials containing 1 ml sterile PBS and one mechanical bead. Tissue samples were homogenised using the tissue lyser II at a frequency of 30 Hz for 20 minutes. Once homogenised, tissue debris was separated to obtain bacterial cells in suspension by light centrifugation at 1500 rpm for 3 minutes. Bacterial-tissue lysates were serially diluted in Ringer’s solution and plated (50 uL) onto SMAC agar plates supplemented with 15 µg / ml Nalidixic acid. SMAC plates were incubated overnight at 37°C and colonies were counted indicative of bacterial colonisation. RESULTS The GlnH protein plays a role in E. coli attachment To investigate whether the GlnH protein is involved in host cell attachment, the attachment of IPTG-induced BL21 cells expressing rGlnH protein to gastrointestinal cells was compared to that of uninduced BL21 cells. Induced BL21 cells recombinantly expressing the rGlnH showed a four-fold increase in the level of bacterial attachment to both CaCo-2 and HT29 cells compared to uninduced BL21 cells (p = 0.0371; p = 0.0161, Fig 2). This confirms that GlnH plays a role in host cell attachment. GlnH is immunogenic in immunised mice. Having confirmed the purity of the GlnH protein and endotoxin levels (EU / mL) were within acceptable limits (not shown), the protective efficacy of protein GlnH was assessed in an in vivo murine model of E. coli O157:H7 infection. BALB / c mice were immunised three times subcutaneously (s.c.) as shown in the schematic displayed in Figure 2. The GlnH protein was confirmed as a highly immunogenic B-cell antigen following serological analysis of mouse sera. GlnH immunisation, at 10 µg and 50 µg doses, induced strong humoral responses compared to alum only treated mice (p < 0.0001; p = 0.0092; Fig 3B). Female mice were colonised with NCTC12900NalrVTEC prototype strain and immunised mice showed protection from E. coli O157:H7 in terms of reduced faecal shedding 6 d.p.i (Fig 4A) . In addition, immunised mice showed more weight gain (%) post infection challenge (*, p = 0.0228; 0.047 0.0008 from day 2 to 7)(Fig 4B). To examine whether T-cell activation along with a moderate antibody response would enhance E. coli O157Nalr protection over robust antibody production, four groups of female BALB / c mice (6 mice per group) were immunised twice, subcutaneously (s.c.) with 10 µg GlnH in combination with either 1:1 SAS (which stimulates T-cell responses) or alum (a humoral immunity activating adjuvant), or with either adjuvant alone, as depicted in the schematic illustration represented in Figure 5. The GlnH protein was again confirmed as a highly immunogenic B-cell antigen, as strong antibody titres were produced after immunisation with 10 µg per dose. Mice immunised with 10 µg GlnH in combination with either SAS or alum adjuvants produced significantly higher levels of total IgG, IgG1 and IgG2a antibodies compared to mice immunised with adjuvants only (p < 0.0001, Fig. 6), indicating that the adjuvant did not impact on serological response in these mice. In addition, reduced colonisation of the colon were observed at 7 d.p.i in GlnH immunised groups, compared to adjuvant alone treated groups (Fig.7). DISCUSSION To date, vaccine development against VTEC has been quite limited to a small number of virulence factors that tend to be subtype specific and predominately focus on the production of high levels of neutralising antibodies (Th2 Humoral response) to confer protection. The current inventors identified the glutamine binding periplasmic protein (GlnH) as being involved in the attachment of VTEC strain, O157 to two gastrointestinal cell lines (HT29 and CaCo-2) and was not identified in attachment of the commensal E. coli strain, HS. Using an in vitro adherence assay, the GlnH protein was confirmed to play a role in E. coli attachment to HT29 and CaCo-2 cells, which supported GlnH involvement in the bacterial adherence of VTEC O157:H7 strain NCTC12900 to gastrointestinal cells when localised to the outer membrane of the bacterial cell. This in vitro study contributed to the rationale behind selecting GlnH for further analysis by investigating its protective efficacy in mice. The initial immunisation trial showed that the GlnH protein was a highly immunogenic B-cell inducing antigen as high IgG antibody titres were produced at both doses (10 µg and 50 µg) µg, which resulted in a Th2 predominant response. Further immunisation and challenge studies were carried out using female mice only to investigate the protective capability of GlnH with a T-cell inducing Adjuvant (SAS) to elucidate cellular response against VTEC. The Th1 / Th2 response stimulated by GlnH in parallel with T-cell activation (SAS) correlated with reduced levels of NCTC12900Nalrin the GI tracts of female mice 7 d.p.i compared to adjuvant alone with statistical significance (p = 0.0280). However, the GlnH alum combination compared to alum adjuvant alone, was comparable to that when SAS was used as adjuvant. Overall, GlnH in combination with SAS as adjuvant reduced the level of O157 colonisation 1.5 logs respectively relative to that of the GI tracts of mice treated with either adjuvant only. This level of O157 reduction in the GI tract of mice confirmed that recombinant GlnH would be a suitable as a component of a multicomponent vaccine against VTEC. EXAMPLE 3 Detection method of VTEC antigen genes The inventors investigated the prevalence of the four selected antigen genes in VTEC shed from a Californian dairy herd to identify the best candidates that offer cross coverage across VTEC serotypes. The specific objectives were: To examine the prevalence of the identified genes in VTEC shed from cattle, using faecal samples from UC Davis, California, collected from two herds. To develop a high throughput screening method for the rapid detection of the VTEC antigen genes using a hydrolysis probe based multiplex real time PCR method. METHODS Faecal and serum collection, processing, and DNA isolation from Californian herd population A total of 130 dairy cows from a Californian herd population were selected at random from two separate herd pens. Faecal and serum samples were collected simultaneously from each of the 130 cows. Faecal samples (25 grams) were obtained from the rectum of 130 dairy cows and transferred to a 50 ml sterile polypropylene tube and transported directly on ice to the Dairy Epi Lab at VMTRC, California. Fresh faecal samples were plated onto CHROMagarTM medium (CHROMagartm,NJ, USA) selective for VTEC isolation. Sterile cotton swabs soaked in 1X Tris-HCl were used to spread faecal samples onto agar. Plates were incubated for 18-24 h at 37 ° C. After incubation, two separate mauve colonies indicative of VTEC specific colony morphology (represented in image above) were selected and picked per plate for pure colony isolation on bovine blood agar plates and incubated for 24 hours at 37 °C. Two pure colonies per faecal sample were subjected to DNA extraction using Thermo Scientific GeneJET Genomic DNA Purification Kit (K0721, Thermo Scientific, USA). DNA extracts were isolated in 1.5 ml microcentrifuge tubes and stored at -20 °C until departure to UCD Dublin. A quality control measure involved using two non-O157 VTEC strains (E. coli ATCC 43888 and E. coli ATTC 25822) to confirm growth of VTEC on CHROMagarTM medium. Upon arrival of DNA samples, All 238 DNA samples were stored at – 20 °C until processing. Primer and Probe design Forward and reverse primers and the corresponding TaqMan real time PCR probe for each gene were designed using the Integrated DNA Technologies Inc. (IDT) online Primer Quest tool (Primer https: / / www.idtdna.com / site / order / oligoentry) (Table 3). (Probe https: / / www.idtdna.com / site / order / qpcr / primetimeprobes) using the E. coli O157:H7 reference sequence NC_002695 for each gene region of interest; FkpA (ECs4198) GlnH (ECs0889) YiaF (ECs4439) and TerD (ECs1355). Table 3: Primers and Probes The primers and probes, single- and multi-plex compatibility checks were conducted to avoid extendable or non-extendable dimer formations by Integrated DNA Technologies Inc. (IDT), Iowa, USA. Once the primer and probe sets passed the appropriate internal checks for compatibility, individual probes were labelled with reporter molecules so that each of the four gene targets of interest were detected using four separate channels on the Roche Lightcycler 96 RT-PCR machine. Each fluorophore label has a unique excitation and emission wavelength detailed in Table 4. Target genes Fluorophore Wavelength (nm) Excitation Emission fkpA FAM 495 520 glnH HEX 538 555 yiaF TEXTM 615 596 613 terD CY5 648 668 Table 4: Fluorophore label and excitation and emission wavelength A highly efficient dark quencher known as Iowa Black was used for all dyes used in the multiplex reaction. Iowa Black was used in combination with secondary quenchers, ZENTM in the case of both FAM and HEX fluorophores and TAOTM for CY5 fluorophore. Double quenchers reduce the background fluorescence considerably which subsequently increases the sensitivity and end-point signal, including earlier Cq values. Double quenched probes are useful in multiplex assays like this, due to the inclusion of several fluorophores in the same reaction which may lead to higher background fluorescence. Single plex real time PCR amplification The rapid detection of the four antigen genes individually was performed using amplification mixtures including 10 μl 2X PrimeTime gene expression master mix (Integrated DNA Technologies, IDT). A single plex probe based real time PCR assay was designed to validate the efficiency of each primer and probe set by reaction mixtures consisting of 25 ng DNA template (4 μl), forward and reverse primers at a concentration of 400 nM and 200 nM of corresponding probe (as outlined in Table 3) to a final volume of 20 μl. Optimal gene amplification conditions were as follows: Preincubation at 95 °C for 10 minutes, followed by 2 step amplification of 30 cycles comprising; denaturation (10 s at 95 °C) and primer annealing (30 s at 60 °C). After the end of cycling, the material was cooled to 4 °C. Multiplex validation Both single and multiplex assays were run simultaneously to validate the multiplex efficiency. Single plex assays involved individual primer and probe sets for each specific gene in separate reaction wells compared to multiplex assays were all 4 primer and probe sets were applied to the same reaction well. Primer and probe efficiency were validated based on qualitative detection only and were considered valid if the point at which the reaction crossed the threshold within single and multiplex assays differed between no more than 2 cycles. Multiplex real time PCR analysis The rapid detection of the presence of four previously identified antigen genes were performed using an amplification mixture containing 10 μl 2X PrimeTime gene expression master mix (Integrated DNA Technologies, IDT). A quadruplex hydrolysis probe based real time PCR reaction mixture consisted of 25 ng DNA template (4 μl), each set of forward and reverse primers at a concentration of 400 nM and 200 nM of corresponding probe sets (as outlined in Table 1) to a final volume of 20 μl. The optimal gene amplification conditions were as follows: a preincubation at 95 °C for 10 minutes, followed by a 2 step amplification of 30 cycles consisting of; denaturation (10 s at 95 °C) and primer annealing (30 s at 60 °C). After end of cycling, the material was cooled to 40 °C. The “no template” controls using DNase and RNase free water were included in triplicate in each 96 plate assay to assess non-specific amplification or hetero dimer formation. Interpretation of results The presence of each antigen in quadruplex reactions was considered positive by RT-PCR if it crossed the threshold before a crossing point (Cq) of 30 cycles. Amplification plots were detected at each channel on the light cycler specific for each fluorescent probe associated with individual genes. Absence of any of the four genes was considered negative if amplification did not cross the threshold within 30 cycles. RESULTS Determining the presence of four VTEC candidate antigen genes in bovine VTEC shed from cattle, in a population. VTEC confirmation from faecal collection and extraction A total of 130 cows were selected at random from two separate pens (Pen 1: 30 cows; Pen 2: 100 cows) of a large dairy (1100 milking cows) in the San Joaquin Valley in California. Of 130 cows sampled, 119 faecal samples tested positive for VTEC by culture. DNA was isolated from each positive culture and the DNA samples were transported by courier from UC Davis, California to UCD. Prior to multiplex real-time PCR analysis, the level of DNA from each isolate was quantified. The DNA extracted from the Californian isolates ranged from 3 – 37 ng / μl, with a median value of 12.2 ng / μl. The presence of the four selected antigen genes in the Californian herd population were compared with 14 VTEC isolates shed from cattle presented to the School of Veterinary Medicine (SVM), UCD, Dublin. Of the 20 SVM cow faecal samples, 14 samples tested positive for VTEC by culture on Sorbitol MacConkey agar. The DNA was isolated from each positive culture plate and quantified using a nanodrop. The DNA quantification of Dublin isolates ranged from 0.4 – 2.3 μg / μl, with a median value of 1.2 μg / μl. Multiplex real-time PCR validation Single assays of each primer and probe set or in combination for each target gene in a quadruplex assay were evaluated in individual wells simultaneously on 96 well plates to validate the multiplex efficiency of each primer and probe. There was no difference in Cycle threshold (Cq) variation between amplification of target genes in both single and multiplex assays. The Cq between single and multiplex assays for each primer / probe set only differed within an acceptable level of 2 cycles (Table 5). This validates the efficiency of each primer and probe set and highlights a sufficient level of compatibility in combination in a single reaction tube, showing Cq and specificity were not affected when each primer / probe set were combined (Table 5). DNA sample PCR reaction well Average Cq mean ΔCq Single versus Multiplex Singleplex Multiplex fkpAFAM NCTC 14.88667 14.85 0.03667 glnHHEX NCTC 14.46667 14.38667 0.08 Internal control E. coli yiaFTEX NCTC 15.58667 15.14667 0.44 O157:H7 NCTC12900 terDCY5 NCTC 16.68333 16.48667 0.1966 fkpAFAM COW132 13.17 13.06333 0.10667 Test COW ID glnHHEX COW132 15.60333 16.76 1.15667 132A +ve for all 4 genes yiaFTEX COW132 13.67 13.30333 0.36667 terDCY5 COW132 14.91333 14.54667 0.3666 Table 5: Assay evaluation Antigen prevalence in a Californian dairy herd population by quadruplex real time PCR DNA samples isolated from 117 dairy cows were screened by multiplex real time PCR to determine the prevalence of genes for the four identified antigens FkpA, GlnH, YiaF and TerD. Up to 30 VTEC DNA isolates were screened simultaneously on a 96 well plate (1: 1-30A, 2: 101-131A, 3: 132-170A and 4: 172-200A). All four antigen genes were highly prevalent among VTEC DNA isolates in the dairy herd cohort, with 100% prevalence for FkpA and YiaF genes and >96% prevalence for GlnH and TerD genes (Table 6)). Antigen gene prevalence in a subgroup of Dublin dairy cows using hydrolysis probe based quadruplex real time PCR DNA samples isolated from 14 dairy cows provided by UCD Veterinary Medicine Hospital, were screened as a preliminary study to investigate whether there were geographical differences in the presence of the four selected antigen genes across continents. All DNA samples representing individually VTEC colonised cattle were run on a single 96 well plate. Similarly, isolates screened from the 14 cows attending the UCD SVM had a high gene prevalence of 93% for FkpA, GlnH and YiaF. In contrast, the prevalence of the TerD gene was low with only one sample out of 14 tested showing the presence of the TerD gene (7%)(Table 6) Prevalence of antigen genes in dairy cows in California and Dublin. Table 6 below represents the combined prevalence of each selected antigen gene target in both the Californian herd population and in cows that attended the UCD Veterinary Medicine Hospital. Three of four antigen genes including FkpA, GlnH and YiaF were highly prevalent in Californian and Irish dairy cow cohorts (Table 6). Population fkpA-FAM glnH-HEX yiaF-TEX terD-CY5 117 / 117 114 / 117 117 / 117 113 / 117 Californian herd prevalence 100% 97.4% 100% 96.6% 13 / 14 13 / 14 13 / 14 1 / 14 Dublin sample prevalence 93% 93% 93% 7% Table 6: Combined prevalence of each selected antigen gene target. Discussion The hydrolysis (TaqMan) probe based multiplex real time PCR method was designed successfully and confirmed the prevalence of four antigen genes in VTEC shed from dairy cows in both Dublin, Ireland and in California, USA. The multiplex assay was developed for the simultaneous detection of FkpA, GlnH, YiaF and TerD genes as multiplex assays are advantageous compared to single plex assays for high throughput screening, allowing analysis of 30 samples simultaneously on a single 96 well plate in a timeframe of 1.5 hours. The validation involved comparing the Cq values determined for each antigen in single plex with the Cq values identified for each gene in the quadruplex assay using DNA from internal control strain NCTC 12900 and DNA isolated from a bovine VTEC isolate. Cq variation was null (<2 cycles) between single and multiplex assays for each gene, therefore, each primer / probe set were considered efficient and compatible in combination in the one reaction well. The four antigen genes were highly prevalent among VTEC DNA isolates obtained from dairy herd populations (two pens) in California, with 100% prevalence of genes for FkpA and YiaF (117 / 117), and >96% prevalence of genes GlnH (114 / 117) and TerD (113 / 117). Similarly, DNA isolates screened from dairy cows attending the UCD Veterinary Hospital in Dublin had a high gene prevalence of 93% for antigens FkpA, GlnH and YiaF (13 / 14). The high prevalence of antigens FkpA, GlnH and YiaF among dairy herd populations is promising, and indicates that should these vaccine antigens be protective, they may have the potential to offer broad protection against O157 and non-O157 VTEC serotypes and could offer the same level of protection in the US as in Ireland. In contrast, the absence of antigen TerD in Irish isolates (7%, 1 / 14), albeit in a very small sample size, compared to the high prevalence of this antigen among Californian isolates processed, indicates a substantial geographical difference in TerD prevalence. Antigen TerD may be subtype specific. The high level of prevalence associated with fkpA and glnH genes indicates the potential for these antigens to be present in a broad range of VTEC strains. Vaccine formulations including these antigens may offer broad protection 78 against a range of VTEC serotypes. These proteins can also be used in a diagnostic method for VTEC infection in humans and cows. Equivalents The foregoing description details presently preferred embodiments of the present invention. Numerous modifications and variations in practice thereof are expected to occur to those skilled in the art upon consideration of these descriptions. Those modifications and variations are intended to be encompassed within the claims appended hereto.

Claims

Claims 1. A vaccine comprising one or more VTEC immunogens (or a nucleotide or mRNA encoding said immunogen) selected from the group comprising GlnH, YiaF, TerD, PPP, MdtE and putative periplasmic binding transport protein, immunogens.

2. The vaccine of Claim 1, wherein the immunogen is a protein.

3. The vaccine of Claim 1, wherein the immunogen is a polypeptide or peptide.

4. The vaccine of Claim 3, wherein the immunogen is a polypeptide and the polypeptide has an amino acid sequence comprising (or consisting of) a sequence selected from SEQUENCE ID NO.1 to 6, or a therapeutically effective variant thereof having at least 90% sequence identity with the sequence.

5. The vaccine of any one of the preceding claims, comprising two or more VTEC immunogens.

6. The vaccine of any one of the preceding claims, comprising three of more VTEC immunogens.

7. The vaccine of Claim 6, comprising three VTEC immunogens and wherein the immunogens are GlNH, YiaF and TerD.

7. The vaccine of any one of the preceding claims, further comprising one or more adjuvants.

8. The vaccine of any one of the preceding claims, comprising one or more additional antigens.

9. The vaccine of any one of the preceding claims, wherein one of the VTEC immunogens selected is GlnH.

10. The vaccine of any one of the preceding claims, comprising GlnH, YiaF, TerD, PPP, MdtE and putative periplasmic binding transport protein, immunogens.

11. The vaccine of any one of Claims 1 to 4, 7 or 8, comprising one VTEC immunogen which is GlnH.

12. The vaccine of any one of the preceding claims, for use in vaccine therapy to treat or prevent VTEC infection in a mammal.

13. The vaccine for use of Claim 12, wherein the VTEC infection is caused by a VTEC strain selected from the group consisting of VTEC O157:H7, VTEC O26, VTEC O111, VTEC O103, VTEC O45, VTEC O121 and VTEC O145.

14. The vaccine for use of Claim 13, wherein the strain is VTEC O157:H7.

15. The vaccine of any one of Claims 1 to 11, for use in vaccine therapy to treat or prevent HUS in a mammal.

16. The vaccine for use of any one of Claims 12 to 15, wherein the mammal is a human.

17. The vaccine for use of Claim 16, wherein the human is seven years old or younger.

18. The vaccine for use of Claim 17 , wherein the human is 60 years old or older.

19. The vaccine for use of any one of Claims 12 to 15, wherein the mammal is a bovine mammal.

20. A pharmaceutical composition comprising one or more one or more VTEC immunogens (or a nucleotide or mRNA encoding said immunogen) selected from the group comprising GlnH, YiaF, TerD, PPP, MdtE and putative periplasmic binding transport protein, immunogens, optionally comprising a pharmaceutically acceptable excipient.

21. The pharmaceutical composition of Claim 20, or the vaccine or any one of Claims 1 to 11, which is formulated as a nanoparticle or a microparticle.

22. A method for diagnosing VTEC infection in a mammal, said method comprising determining the presence of one or more VTEC proteins (or genes encoding said proteins, or antibodies specific to said proteins) selected from the group comprising GlnH, FkpA, YiaF, TerD, PPP, MdtE and putative periplasmic binding transport protein in a sample from the mammal, wherein presence of said one or more proteins (or genes encoding said proteins) in the sample is indicative of VTEC infection.

23. The method of Claim 22, wherein the VTEC proteins selected are FkpA, GlnH, YiaF.

24. The method of Claim 22, wherein the VTEC proteins selected are FkpA, GlnH, YiaF and TerD.

25. A method of vaccinating a subject to prevent VTEC infection, comprising administering to the subject a vaccine of any one of Claims 1 to 11 or 21.

26. A method of treating VTEC infection in a subject, comprising administering to the subject a vaccine of any one of Claims 1 to 11, or 21, or the pharmaceutical composition of Claim 20 to 21.

27. A method of vaccinating a subject to prevent HUS, comprising administering to the subject a vaccine of any one of Claims 1 to 11 or 21.